1
|
Chen X, Wei MM, Zhang ZX, Liu G, Wang RS, You XY, Hu DS, Zhao Y. [Association of triglyceride glucose index and risk of incident hypertension: a prospective cohort study]. Zhonghua Xin Xue Guan Bing Za Zhi 2024; 52:413-419. [PMID: 38644257 DOI: 10.3760/cma.j.cn112148-20230911-00149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/23/2024]
Abstract
Objective: To explore the relationship between the triglyceride glucose (TyG) index and the risk of developing hypertension among rural Chinese adults. Methods: A prospective cohort study was conducted from 2007 to 2008, involving 20 194 adults selected through random cluster sampling from a rural community in Luoyang City, Henan Province. Follow-ups were carried out in 2013-2014 and 2018-2020. After excluding participants with hypertension at baseline, those with missing TyG index data, individuals who passed away during follow-up, and those with incomplete hypertension status at the second visit, 9 802 participants were included in the analysis. Baseline and follow-up assessments included questionnaire interviews, physical measurements (including blood pressure), and blood sample collection for fasting lipid and glucose levels. Participants were divided into four groups according to TyG index quartiles, and a modified Poisson regression model was utilized to assess the association between TyG index quartiles and hypertension risk. Results: The study cohort comprised 9 802 participants with a median age of 48 (39, 57) years, including 3 803 males (38.80%). Participants were distributed across TyG index quartiles as follows: TyG<8.2 group (2 224 individuals), TyG 8.2-8.5 group (2 653 individuals), TyG 8.6-8.9 (2 441 individuals), and TyG≥9.0 (2 484 individuals). Over a follow-up period of (11.1±1.3) years, 3 378 subjects developed hypertension, resulting in a cumulative incidence of 34.46% (3 378/9 802). The risk of hypertension increased with higher TyG index quartiles (Ptrend<0.05). Compared to the TyG<8.2, the TyG 8.2-8.5 (RR=1.11, 95%CI 1.01-1.22, P=0.023), TyG 8.6-8.9 (RR=1.16, 95%CI 1.06-1.27, P=0.023), and TyG≥9.0 (RR=1.20, 95%CI 1.10-1.31, P=0.023) exhibited increased hypertension risk after adjusting for age, gender, educational level, and other potential confounders. Subgroup analyses based on gender and age at baseline yielded results consistent with the main analysis. Conclusions: The TyG index is positively correlated with the risk of developing hypertension in the rural adult population.
Collapse
Affiliation(s)
- X Chen
- Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou 450000, China
| | - M M Wei
- Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou 450000, China
| | - Z X Zhang
- Henan Provincial Chest Hospital, Zhengzhou University, Zhengzhou 450000, China
| | - G Liu
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
| | - R S Wang
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
| | - X Y You
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
| | - D S Hu
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
| | - Y Zhao
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
| |
Collapse
|
2
|
Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun 2024; 15:3038. [PMID: 38589351 PMCID: PMC11002015 DOI: 10.1038/s41467-024-45814-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/10/2024] Open
Affiliation(s)
- Bradley A Maron
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
| | - Rui-Sheng Wang
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Sergei Shevtsov
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Stavros G Drakos
- Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Elena Arons
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Omar Wever-Pinzon
- Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Gordon S Huggins
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Andriy O Samokhin
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - William M Oldham
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Yasmine Aguib
- Department of Cardiac Surgery, Imperial College of London, London, UK
- The Magdi Yacoub Heart Center, Aswan, Egypt
| | - Magdi H Yacoub
- Department of Cardiac Surgery, Imperial College of London, London, UK
- The Magdi Yacoub Heart Center, Aswan, Egypt
| | - Ethan J Rowin
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Barry J Maron
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Martin S Maron
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Joseph Loscalzo
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| |
Collapse
|
3
|
Zhang LQ, Wang C, Baumjohann W, Wang RS, Wang JY, Burch JL, Khotyaintsev YV. First observation of fluid-like eddy-dominant bursty bulk flow turbulence in the Earth's tail plasma sheet. Sci Rep 2023; 13:19201. [PMID: 37932297 PMCID: PMC10628178 DOI: 10.1038/s41598-023-45867-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Accepted: 10/25/2023] [Indexed: 11/08/2023] Open
Abstract
Turbulence is a ubiquitous phenomenon in neutral and conductive fluids. According to classical theory, turbulence is a rotating flow containing vortices of different scales. Eddies play a fundamental role in the nonlinear cascade of kinetic energy at different scales in turbulent flow. In conductive fluids, the Alfvénic/kinetic Alfvénic wave (AW/KAW) is the new "cell" of magnetohydrodynamic (MHD) turbulence (frozen-in condition). Wave energy, which has equal kinetic and magnetic energy, is redistributed among multiple-scale Fourier modes and transferred from the large MHD scale to the small kinetic scale through the collision of counter-propagating Alfvénic wave packages propagating along the magnetic field line. Fluid-like eddy-dominant plasma flow turbulence has never been found in space since the launch of the first satellite in 1957. In this paper, we report the first observation of eddy-dominant turbulence within magnetic reconnection-generated fast flow in the Earth's tail plasma sheet by the Magnetospheric Multiscale Spacecraft (MMS). In eddy-dominant turbulent reconnection jet, ions dominate the flow field while electrons dominate current and magnetic fluctuations. Our findings shed new light on the nonlinear kinetic and magnetic energy cascade in MHD turbulence.
Collapse
Affiliation(s)
- L Q Zhang
- State Key Laboratory of Space Weather, National Space Science Center, Chinese Academy of Sciences, Beijing, 100080, China
| | - Chi Wang
- State Key Laboratory of Space Weather, National Space Science Center, Chinese Academy of Sciences, Beijing, 100080, China.
| | - W Baumjohann
- Space Research Institute, Austrian Academy of Sciences, 8042, Graz, Austria
| | - R S Wang
- CAS KCAS Key Laboratory of Geospace Environment, Department of Geophysics and Planetary Science, University of Science and Technology of China, Hefei, 230026, China
| | - J Y Wang
- Information Engineering College, Central University for Nationalities, Beijing, 100081, China
| | - James L Burch
- Southwest Research Institute San Antonio, San Antonio, TX, 78238, USA
| | | |
Collapse
|
4
|
Wang RS, Huang S, Waldo SW, Hess E, Gokhale M, Johnson SW, Zeder K, Choudhary G, Leopold JA, Oldham WM, Kovacs G, Freiberg MS, Tedford RJ, Maron BA, Brittain EL. Elevated Pulmonary Arterial Compliance Is Associated with Survival in Pulmonary Hypertension: Results from a Novel Network Medicine Analysis. Am J Respir Crit Care Med 2023; 208:312-321. [PMID: 37276608 PMCID: PMC10395727 DOI: 10.1164/rccm.202211-2097oc] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 05/31/2023] [Indexed: 06/07/2023] Open
Abstract
Rationale: Predictors of adverse outcome in pulmonary hypertension (PH) are well established; however, data that inform survival are lacking. Objectives: We aim to identify clinical markers and therapeutic targets that inform the survival in PH. Methods: We included data from patients with elevated mean pulmonary artery pressure (mPAP) diagnosed by right heart catheterization in the U.S. Veterans Affairs system (October 1, 2006-September 30, 2018). Network medicine framework was used to subgroup patients when considering an N of 79 variables per patient. The results informed outcome analyses in the discovery cohort and a sex-balanced validation right heart catheterization cohort from Vanderbilt University (September 24, 1998-December 20, 2013). Measurements and Main Results: From an N of 4,737 complete case patients with mPAP of 19-24 mm Hg, there were 21 distinct subgroups (network modules) (all-cause mortality range = 15.9-61.2% per module). Pulmonary arterial compliance (PAC) drove patient assignment to modules characterized by increased survival. When modeled continuously in patients with mPAP ⩾19 mm Hg (N = 37,744; age, 67.2 yr [range = 61.7-73.8 yr]; 96.7% male; median follow-up time, 1,236 d [range = 570-1,971 d]), the adjusted all-cause mortality hazard ratio was <1.0 beginning at PAC ⩾3.0 ml/mm Hg and decreased progressively to ∼7 ml/mm Hg. A protective association between PAC ⩾3.0 ml/mm Hg and mortality was also observed in the validation cohort (N = 1,514; age, 60.2 yr [range = 49.2-69.1 yr]; 48.0% male; median follow-up time, 2,485 d [range = 671-3,580 d]). The association was strongest in patients with precapillary PH at the time of catheterization, in whom 41% (95% confidence interval, 0.55-0.62; P < 0.001) and 49% (95% confidence interval, 0.38-0.69; P < 0.001) improvements in survival were observed for PAC ⩾3.0 versus <3.0 ml/mm Hg in the discovery and validation cohorts, respectively. Conclusions: These data identify elevated PAC as an important parameter associated with survival in PH. Prospective studies are warranted that consider PAC ⩾3.0 ml/mm Hg as a therapeutic target to achieve through proven interventions.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Division of Cardiovascular Medicine
- Channing Division of Network Medicine, and
| | | | - Stephen W. Waldo
- Department of Medicine, Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado
- Veterans Affairs Clinical Assessment, Reporting, and Tracking Program, Veterans Health Administration Office of Quality and Patient Safety, Washington, DC
- Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
| | - Edward Hess
- Department of Medicine, Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado
| | - Madhura Gokhale
- Department of Medicine, Cardiology Section, Rocky Mountain Regional VA Medical Center, Aurora, Colorado
| | - Shelsey W. Johnson
- Department of Pulmonary and Critical Care, Boston Medical Center, Boston, Massachusetts
| | - Katarina Zeder
- Department of Pulmonology, Medical University of Graz and Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
| | - Gaurav Choudhary
- Providence Veterans Affairs Medical Center and Division of Cardiovascular Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island
| | | | - William M. Oldham
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| | - Gabor Kovacs
- Department of Pulmonology, Medical University of Graz and Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
| | - Matthew S. Freiberg
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
- Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee
| | - Ryan J. Tedford
- Division of Cardiology, Medical Department of Medicine, University of South Carolina, Charleston, South Carolina; and
| | - Bradley A. Maron
- Division of Cardiovascular Medicine
- Veterans Affairs Boston Healthcare System, Boston, Massachusetts
| | - Evan L. Brittain
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| |
Collapse
|
5
|
Amamoto T, Toyooka T, Yamada M, Yanagiba Y, Wang RS, Koda S. [Investigating erythrocyte hemolysis assay use for proinflammatory potential prediction of silica particles]. Sangyo Eiseigaku Zasshi 2023; 65:125-133. [PMID: 35831134 DOI: 10.1539/sangyoeisei.2021-043-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
OBJECTIVES Crystalline silica, which is a causative agent of silicosis (an occupational disease), is manufactured in a variety of products (particles) with different particle characteristics, such as size and surface properties. In Japan, the products are currently uniformly controlled as crystalline silica, which is a substance subject to labeling and notification requirements. However, since the toxicity of silica particles reportedly varies depending on its characteristics, businesses are encouraged to conduct appropriate risk assessments for each product to prevent silicosis. Recently, silica particles have been reported to induce lysosomal membrane damage, leading to the activation of proinflammatory factors. An indirect method to evaluate lysosomal membrane damage known as the erythrocyte hemolysis assay, in which the erythrocyte membrane is assumed to be the lysosomal membrane, was performed. This study aimed to examine the possibility of constructing a screening system for proinflammatory potential prediction of silica particles based on their erythrocyte hemolytic activity. METHODS Hemolysis assays were performed on the silica particles with different sizes, crystallinity, and surface functional groups using the erythrocytes from a healthy volunteer. Additionally, the hemolytic activity of other element particles was compared with that of the silica particles, and 27 types of commercially available crystalline silica particle products underwent screening trials. RESULTS The hemolytic activity of silica particles was higher in crystalline than that in amorphous and increased with the decreasing size. The hemolytic reaction was particular to silica particles and rarely occurred in particles of other elements. Moreover, the hemolytic activity was significantly suppressed if the silica particles surface was modified with metal ions (Fe3+, Al3+). The hemolytic activities of the crystalline silica products used industrially significantly differed. CONCLUSIONS This study revealed that particle properties, such as size, crystallinity, and surface functional groups, affect the hemolytic activity of silica particles. Particularly, the surface functional groups (silanol groups) that are unique to silica particles were considered to be strongly involved in hemolytic activities. Since grading the commercially available crystalline silica particle products based on the hemolytic rate was possible, hemolytic activity was suggested to be an evaluation index for predicting the proinflammatory potential of silica particles.
Collapse
Affiliation(s)
- Takaki Amamoto
- National Institute of Occupational Safety and Health, Japan
| | | | - Maromu Yamada
- National Institute of Occupational Safety and Health, Japan
| | - Yukie Yanagiba
- National Institute of Occupational Safety and Health, Japan
| | - Rui-Sheng Wang
- National Institute of Occupational Safety and Health, Japan
| | - Shigeki Koda
- National Institute of Occupational Safety and Health, Japan
| |
Collapse
|
6
|
Wang RS, Loscalzo J. Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations. Circ Res 2023; 132:1374-1386. [PMID: 37167362 PMCID: PMC10171294 DOI: 10.1161/circresaha.122.321879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
COVID-19 is an infectious disease caused by SARS-CoV-2 leading to the ongoing global pandemic. Infected patients developed a range of respiratory symptoms, including respiratory failure, as well as other extrapulmonary complications. Multiple comorbidities, including hypertension, diabetes, cardiovascular diseases, and chronic kidney diseases, are associated with the severity and increased mortality of COVID-19. SARS-CoV-2 infection also causes a range of cardiovascular complications, including myocarditis, myocardial injury, heart failure, arrhythmias, acute coronary syndrome, and venous thromboembolism. Although a variety of methods have been developed and many clinical trials have been launched for drug repositioning for COVID-19, treatments that consider cardiovascular manifestations and cardiovascular disease comorbidities specifically are limited. In this review, we summarize recent advances in drug repositioning for COVID-19, including experimental drug repositioning, high-throughput drug screening, omics data-based, and network medicine-based computational drug repositioning, with particular attention on those drug treatments that consider cardiovascular manifestations of COVID-19. We discuss prospective opportunities and potential methods for repurposing drugs to treat cardiovascular complications of COVID-19.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Channing Division of Network Medicine (R.-S.W., J.L.), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, MA
| | - Joseph Loscalzo
- Channing Division of Network Medicine (R.-S.W., J.L.), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, MA
- Division of Cardiovascular Medicine (J.L.), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School Boston, MA
| |
Collapse
|
7
|
Wang RS, Rowin EJ, Maron BJ, Maron MS, Maron BA. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. Cardiovasc Res 2023; 119:e125-e127. [PMID: 37129987 PMCID: PMC10409890 DOI: 10.1093/cvr/cvad036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/03/2023] Open
Affiliation(s)
- Rui-Sheng Wang
- Division of Cardiovascular Medicine, Department of Medicine, 77 Ave Louis Pasteur, NRB 0630-N, Boston, MA 02115, USA
- Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Ethan J Rowin
- HCM Center, Lahey Hospital and Medical Center, Burlington, MA 01805, USA
| | - Barry J Maron
- HCM Center, Lahey Hospital and Medical Center, Burlington, MA 01805, USA
| | - Martin S Maron
- HCM Center, Lahey Hospital and Medical Center, Burlington, MA 01805, USA
| | - Bradley A Maron
- Division of Cardiovascular Medicine, Department of Medicine, 77 Ave Louis Pasteur, NRB 0630-N, Boston, MA 02115, USA
| |
Collapse
|
8
|
Li DH, Wang RS, Zhang ZL, Zhu JG, Sun MM, Qiao J. [Difference of lipid-lowering efficacy of "Xinjianqu" before and after fermentation and its mechanism based on LKB1-AMPK pathway and 16S rDNA sequencing technology]. Zhongguo Zhong Yao Za Zhi 2023; 48:2146-2159. [PMID: 37282903 DOI: 10.19540/j.cnki.cjcmm.20230112.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
On the basis of establishing the prescription of Xinjianqu and clarifying the increase of the lipid-lowering active ingredients of Xinjianqu by fermentation, this paper further compared the differences in the lipid-lowering effects of Xinjianqu before and after fermentation, and studied the mechanism of Xinjianqu in the treatment of hyperlipidemia. Seventy SD rats were randomly divided into seven groups, including normal group, model group, positive drug simvastatin group(0.02 g·kg~(-1)), and low-dose and high-dose Xinjianqu groups before and after fermentation(1.6 g·kg~(-1) and 8 g·kg~(-1)), with ten rats in each group. Rats in each group were given high-fat diet continuously for six weeks to establish the model of hyperlipidemia(HLP). After successful modeling, the rats were given high-fat diet and gavaged by the corresponding drugs for six weeks, once a day, to compare the effects of Xinjianqu on the body mass, liver coefficient, and small intestine propulsion rate of rats with HLP before and after fermentation. The effects of Xinjianqu before and after fermentation on total cholesterol(TC), triacylglyceride(TG), high-density lipoprotein cholesterol(HDL-C), low-density lipoprotein cholesterol(LDL-C), alanine aminotransferase(ALT), aspartate aminotransferase(AST), blood urea nitrogen(BUN), creatinine(Cr), motilin(MTL), gastrin(GAS), and the Na~+-K~+-ATPase levels were determined by enzyme-linked immunosorbent assay(ELISA). The effects of Xinjianqu on liver morphology of rats with HLP were investigated by hematoxylin-eosin(HE) staining and oil red O fat staining. The effects of Xinjianqu on the protein expression of adenosine 5'-monophosphate(AMP)-activated protein kinase(AMPK), phosphorylated AMPK(p-AMPK), liver kinase B1(LKB1), and 3-hydroxy-3-methylglutarate monoacyl coenzyme A reductase(HMGCR) in liver tissues were investigated by immunohistochemistry. The effects of Xinjianqu on the regulation of intestinal flora structure of rats with HLP were studied based on 16S rDNA high-throughput sequencing technology. The results showed that compared with those in the normal group, rats in the model group had significantly higher body mass and liver coefficient(P<0.01), significantly lower small intestine propulsion rate(P<0.01), significantly higher serum levels of TC, TG, LDL-C, ALT, AST, BUN, Cr, and AQP2(P<0.01), and significantly lower serum levels of HDL-C, MTL, GAS, Na~+-K~+-ATP levels(P<0.01). The protein expression of AMPK, p-AMPK, and LKB1 in the livers of rats in the model group was significantly decreased(P<0.01), and that of HMGCR was significantly increased(P<0.01). In addition, the observed_otus, Shannon, and Chao1 indices were significantly decreased(P<0.05 or P<0.01) in rat fecal flora in the model group. Besides, in the model group, the relative abundance of Firmicutes was reduced, while that of Verrucomicrobia and Proteobacteria was increased, and the relative abundance of beneficial genera such as Ligilactobacillus and Lachnospiraceae_NK4A136_group was reduced. Compared with the model group, all Xinjianqu groups regulated the body mass, liver coefficient, and small intestine index of rats with HLP(P<0.05 or P<0.01), reduced the serum levels of TC, TG, LDL-C, ALT, AST, BUN, Cr, and AQP2, increased the serum levels of HDL-C, MTL, GAS, and Na~+-K~+-ATP, improved the liver morphology, and increased the protein expression gray value of AMPK, p-AMPK, and LKB1 in the liver of rats with HLP and decreased that of LKB1. Xinjianqu groups could regulate the intestinal flora structure of rats with HLP, increased observed_otus, Shannon, Chao1 indices, and increased the relative abundance of Firmicutes, Ligilactobacillus(genus), Lachnospiraceae_NK4A136_group(genus). Besides, the high-dose Xinjianqu-fermented group had significant effects on body mass, liver coefficient, small intestine propulsion rate, and serum index levels of rats with HLP(P<0.01), and the effects were better than those of Xinjianqu groups before fermentation. The above results show that Xinjianqu can improve the blood lipid level, liver and kidney function, and gastrointestinal motility of rats with HLP, and the improvement effect of Xinjianqu on hyperlipidemia is significantly enhanced by fermentation. The mechanism may be related to AMPK, p-AMPK, LKB1, and HMGCR protein in the LKB1-AMPK pathway and the regulation of intestinal flora structure.
Collapse
Affiliation(s)
- De-Hua Li
- Henan University of Chinese Medicine Zhengzhou 450046, China Henan Research Center for Special Processing Technology of Chinese Medicine Zhengzhou 450046, China
| | - Rui-Sheng Wang
- Henan University of Chinese Medicine Zhengzhou 450046, China Henan Research Center for Special Processing Technology of Chinese Medicine Zhengzhou 450046, China
| | - Zhen-Ling Zhang
- Henan University of Chinese Medicine Zhengzhou 450046, China Henan Research Center for Special Processing Technology of Chinese Medicine Zhengzhou 450046, China Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-constructed by Henan province & Education Ministry of China Zhengzhou 450046, China
| | - Jian-Guang Zhu
- Henan University of Chinese Medicine Zhengzhou 450046, China Henan Research Center for Special Processing Technology of Chinese Medicine Zhengzhou 450046, China
| | - Meng-Mei Sun
- Henan University of Chinese Medicine Zhengzhou 450046, China Henan Research Center for Special Processing Technology of Chinese Medicine Zhengzhou 450046, China
| | - Jia Qiao
- Henan University of Chinese Medicine Zhengzhou 450046, China Henan Research Center for Special Processing Technology of Chinese Medicine Zhengzhou 450046, China
| |
Collapse
|
9
|
Wang RS, Maron BA, Loscalzo J. Multiomics Network Medicine Approaches to Precision Medicine and Therapeutics in Cardiovascular Diseases. Arterioscler Thromb Vasc Biol 2023; 43:493-503. [PMID: 36794589 PMCID: PMC10038904 DOI: 10.1161/atvbaha.122.318731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 01/30/2023] [Indexed: 02/17/2023]
Abstract
Cardiovascular diseases (CVD) are the leading cause of death worldwide and display complex phenotypic heterogeneity caused by many convergent processes, including interactions between genetic variation and environmental factors. Despite the identification of a large number of associated genes and genetic loci, the precise mechanisms by which these genes systematically influence the phenotypic heterogeneity of CVD are not well understood. In addition to DNA sequence, understanding the molecular mechanisms of CVD requires data from other omics levels, including the epigenome, the transcriptome, the proteome, as well as the metabolome. Recent advances in multiomics technologies have opened new precision medicine opportunities beyond genomics that can guide precise diagnosis and personalized treatment. At the same time, network medicine has emerged as an interdisciplinary field that integrates systems biology and network science to focus on the interactions among biological components in health and disease, providing an unbiased framework through which to integrate systematically these multiomics data. In this review, we briefly present such multiomics technologies, including bulk omics and single-cell omics technologies, and discuss how they can contribute to precision medicine. We then highlight network medicine-based integration of multiomics data for precision medicine and therapeutics in CVD. We also include a discussion of current challenges, potential limitations, and future directions in the study of CVD using multiomics network medicine approaches.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Division of Cardiovascular Medicine
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| | | | - Joseph Loscalzo
- Division of Cardiovascular Medicine
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
10
|
Wertheim BM, Wang RS, Guillermier C, Hütter CV, Oldham WM, Menche J, Steinhauser ML, Maron BA. Proline and glucose metabolic reprogramming supports vascular endothelial and medial biomass in pulmonary arterial hypertension. JCI Insight 2023; 8:163932. [PMID: 36626231 PMCID: PMC9977503 DOI: 10.1172/jci.insight.163932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 01/05/2023] [Indexed: 01/11/2023] Open
Abstract
In pulmonary arterial hypertension (PAH), inflammation promotes a fibroproliferative pulmonary vasculopathy. Reductionist studies emphasizing single biochemical reactions suggest a shift toward glycolytic metabolism in PAH; however, key questions remain regarding the metabolic profile of specific cell types within PAH vascular lesions in vivo. We used RNA-Seq to profile the transcriptome of pulmonary artery endothelial cells (PAECs) freshly isolated from an inflammatory vascular injury model of PAH ex vivo, and these data were integrated with information from human gene ontology pathways. Network medicine was then used to map all aa and glucose pathways to the consolidated human interactome, which includes data on 233,957 physical protein-protein interactions. Glucose and proline pathways were significantly close to the human PAH disease module, suggesting that these pathways are functionally relevant to PAH pathobiology. To test this observation in vivo, we used multi-isotope imaging mass spectrometry to map and quantify utilization of glucose and proline in the PAH pulmonary vasculature at subcellular resolution. Our findings suggest that elevated glucose and proline avidity underlie increased biomass in PAECs and the media of fibrosed PAH pulmonary arterioles. Overall, these data show that anabolic utilization of glucose and proline are fundamental to the vascular pathology of PAH.
Collapse
Affiliation(s)
| | - Rui-Sheng Wang
- Division of Cardiovascular Medicine, Department of Medicine.,Channing Division of Network Medicine, Department of Medicine; and
| | - Christelle Guillermier
- Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Center for NanoImaging, Cambridge, Massachusetts, USA
| | - Christiane Vr Hütter
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.,Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Vienna, Austria.,Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and the Medical University of Vienna, Vienna, Austria
| | - William M Oldham
- Division of Pulmonary and Critical Medicine, Department of Medicine
| | - Jörg Menche
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.,Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Vienna, Austria.,Faculty of Mathematics, University of Vienna, Vienna, Austria
| | - Matthew L Steinhauser
- Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Center for NanoImaging, Cambridge, Massachusetts, USA.,Division of Cardiovascular Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.,Aging Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | | |
Collapse
|
11
|
Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Author Correction: Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun 2022; 13:7026. [PMID: 36396654 PMCID: PMC9672304 DOI: 10.1038/s41467-022-34834-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
12
|
Maron BA, Wang RS, Carnethon MR, Rowin EJ, Loscalzo J, Maron BJ, Maron MS. What Causes Hypertrophic Cardiomyopathy? Am J Cardiol 2022; 179:74-82. [PMID: 35843734 DOI: 10.1016/j.amjcard.2022.06.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 05/31/2022] [Accepted: 06/15/2022] [Indexed: 01/11/2023]
Abstract
Hypertrophic cardiomyopathy (HCM) is a global and relatively common cause of patient morbidity and mortality and is among the first reported monogenic cardiac diseases. For 30 years, the basic etiology of HCM has been attributed largely to variants in individual genes encoding cardiac sarcomere proteins, with the implication that HCM is fundamentally a genetic disease. However, data from clinical and network medicine analyses, as well as contemporary genetic studies show that single gene variants do not fully explain the broad and diverse HCM clinical spectrum. These transformative advances place a new focus on possible novel interactions between acquired disease determinants and genetic context to produce complex HCM phenotypes, also offering a measure of caution against overemphasizing monogenics as the principal cause of this disease. These new perspectives in which HCM is not a uniformly genetic disease but likely explained by multifactorial etiology will also unavoidably impact how HCM is viewed by patients and families in the clinical practicing community going forward, including relevance to genetic counseling and access to healthcare insurance and psychosocial wellness.
Collapse
Affiliation(s)
- Bradley A Maron
- Division of Cardiovascular Medicine, Department of Medicine and Harvard Medical School, Boston, Massachusetts.
| | - Rui-Sheng Wang
- Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Mercedes R Carnethon
- Division of Pulmonology and Critical Care, Feinberg School of Medicine, Chicago, Illinois
| | - Ethan J Rowin
- HCM Center, Lahey Hospital and Medical Center, Burlington, Massachusetts
| | - Joseph Loscalzo
- Division of Cardiovascular Medicine, Department of Medicine and Harvard Medical School, Boston, Massachusetts
| | - Barry J Maron
- HCM Center, Lahey Hospital and Medical Center, Burlington, Massachusetts
| | - Martin S Maron
- HCM Center, Lahey Hospital and Medical Center, Burlington, Massachusetts
| |
Collapse
|
13
|
Xu QT, Guo JX, Jiangping R, Wang RS, Ma JL, Zhou J. [Application value of combined deep inhalation and breath-hold technique guided by four-dimensional CT in preoperative localization of solitary pulmonary nodules]. Zhonghua Yi Xue Za Zhi 2022; 102:1278-1282. [PMID: 35488696 DOI: 10.3760/cma.j.cn112137-20211116-02558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To explore the clinical value of four dimensional computed tomography (4 D CT) guided combined with deep inhalation and breath hold (DIBH) technique in the preoperative localization of solitary pulmonary nodules. Methods: The data of a total of 106 patients with solitary pulmonary nodules from March 2018 to May 2021 in the Ningbo First Hospital were collected retrospectively. Among them, there were 26 males and 80 females aged from 21 to 83 (47.4±14.2) years. According to different localization methods, 53 cases were divided into the control group, as the pulmonary nodules were located by CT guided injection of indocyanine green under calm breathing and 53 cases were divided into in the experimental group, as those patients were treated with indocyanine green injection under the guidance of 4 D CT combined with DIBH technology to locate pulmonary nodules. The three-dimensional distance deviation between pulmonary nodules and indocyanine green injection points was compared between the two groups to obtain the accuracy of pulmonary nodule localization. The preoperative positioning time of the two groups was compared by timing. Results: Among the 106 patients, there were 46 pure ground glass nodules, 32 sub solid nodules and 28 solid nodules, all of which were successfully localized before operation, with a success rate of 100%. The size of pulmonary nodules in the control group was (9.1±2.3) mm and the three-dimensional deviation[M(Q1, Q3)]between indocyanine green injection site and pulmonary nodules was X axis [7.0 (3.7, 12.6)] mm, Y axis [6.6 (2.9, 11.2)] mm, Z axis [3.0 (2.0, 6.0)]mm, respectively, and the preoperative positioning time was (11.4±3.8) min. The size of pulmonary nodules in the experimental group was (8.9±2.1) mm, and the deviations in 3 D direction were X axis [4.8 (3.0, 7.9)]mm, Y axis [3.8 (1.3, 7.5)]mm, Z axis [4.0 (2.0, 6.0)] mm, respectively. The preoperative positioning time was (9.3±3.0) min. There were statistically significant differences in preoperative positioning time and deviation of X and Y axis between the experimental group and the control group (P<0.05), but no statistically significant differences was found in deviation of Z axis (P>0.05). Conclusion: 4 D CT guided DIBH technology could improve the accuracy of preoperative localization of pulmonary nodules and save operation time, which is worthy of popularization.
Collapse
Affiliation(s)
- Q T Xu
- Department of Oncology and Chemoradiotherapy, Ningbo First Hospital, Ningbo 315000, China
| | - J X Guo
- Department of Oncology and Chemoradiotherapy, Ningbo First Hospital, Ningbo 315000, China
| | - Ren Jiangping
- Department of Oncology and Chemoradiotherapy, Ningbo First Hospital, Ningbo 315000, China
| | - R S Wang
- Department of Thoracic Surgery, Ningbo First Hospital, Ningbo 315000, China
| | - J L Ma
- Department of Oncology and Chemoradiotherapy, Ningbo First Hospital, Ningbo 315000, China
| | - Jianliang Zhou
- Department of Oncology and Chemoradiotherapy, Ningbo First Hospital, Ningbo 315000, China
| |
Collapse
|
14
|
Paci P, Fiscon G, Conte F, Wang RS, Handy DE, Farina L, Loscalzo J. Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects. NPJ Syst Biol Appl 2022; 8:12. [PMID: 35443763 PMCID: PMC9021283 DOI: 10.1038/s41540-022-00221-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 03/19/2022] [Indexed: 12/28/2022] Open
Abstract
Despite advances in modern medicine that led to improvements in cardiovascular outcomes, cardiovascular disease (CVD) remains the leading cause of mortality and morbidity globally. Thus, there is an urgent need for new approaches to improve CVD drug treatments. As the development time and cost of drug discovery to clinical application are excessive, alternate strategies for drug development are warranted. Among these are included computational approaches based on omics data for drug repositioning, which have attracted increasing attention. In this work, we developed an adjusted similarity measure implemented by the algorithm SAveRUNNER to reposition drugs for cardiovascular diseases while, at the same time, considering the side effects of drug candidates. We analyzed nine cardiovascular disorders and two side effects. We formulated both disease disorders and side effects as network modules in the human interactome, and considered those drug candidates that are proximal to disease modules but far from side-effects modules as ideal. Our method provides a list of drug candidates for cardiovascular diseases that are unlikely to produce common, adverse side-effects. This approach incorporating side effects is applicable to other diseases, as well.
Collapse
Affiliation(s)
- Paola Paci
- Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy. .,Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy.
| | - Giulia Fiscon
- Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy.,Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy
| | - Federica Conte
- Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy
| | - Rui-Sheng Wang
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| | - Diane E Handy
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| | - Lorenzo Farina
- Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy
| | - Joseph Loscalzo
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| |
Collapse
|
15
|
Lu Y, Xue G, Zheng N, Han K, Yang W, Wang RS, Wu L, Miller LD, Pardee T, Triozzi PL, Lo HW, Watabe K, Wong STC, Pasche BC, Zhang W, Jin G. hDirect-MAP: projection-free single-cell modeling of response to checkpoint immunotherapy. Brief Bioinform 2022; 23:6509049. [PMID: 35037026 PMCID: PMC8921624 DOI: 10.1093/bib/bbab575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 12/13/2021] [Accepted: 12/15/2021] [Indexed: 01/19/2023] Open
Abstract
There is a lack of robust generalizable predictive biomarkers of response to immune checkpoint blockade in multiple types of cancer. We develop hDirect-MAP, an algorithm that maps T cells into a shared high-dimensional (HD) expression space of diverse T cell functional signatures in which cells group by the common T cell phenotypes rather than dimensional reduced features or a distorted view of these features. Using projection-free single-cell modeling, hDirect-MAP first removed a large group of cells that did not contribute to response and then clearly distinguished T cells into response-specific subpopulations that were defined by critical T cell functional markers of strong differential expression patterns. We found that these grouped cells cannot be distinguished by dimensional-reduction algorithms but are blended by diluted expression patterns. Moreover, these identified response-specific T cell subpopulations enabled a generalizable prediction by their HD metrics. Tested using five single-cell RNA-seq or mass cytometry datasets from basal cell carcinoma, squamous cell carcinoma and melanoma, hDirect-MAP demonstrated common response-specific T cell phenotypes that defined a generalizable and accurate predictive biomarker.
Collapse
Affiliation(s)
- Yong Lu
- Corresponding authors: Yong Lu, Cancer Center, Weill Cornell Medicine, Houston Methodist Hospital, Houston, TX 77030, USA. E-mail: ; Wei Zhang, Department of Cancer Biology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel.: 336.713.7508; E-mail: ; Guangxu Jin, Department of Cancer Biology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel.: 336.713.7515; E-mail:
| | | | - Ningbo Zheng
- Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, China
| | - Kun Han
- Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC 27101, China
| | - Wenzhong Yang
- Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, China
| | - Rui-Sheng Wang
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, China
| | - Lingyun Wu
- Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing, China
| | - Lance D Miller
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China,Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, China
| | - Timothy Pardee
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China,Section of Hematology and Oncology, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, 27157, China
| | - Pierre L Triozzi
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China,Section of Hematology and Oncology, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, 27157, China
| | - Hui-Wen Lo
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China,Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, China
| | - Kounosuke Watabe
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China,Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, China
| | - Stephen T C Wong
- Departments of Pathology and Genome Medicine, Weill Cornell Medicine, Houston Methodist Hospital, Houston, TX 77030, China
| | - Boris C Pasche
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, China,Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, China
| | - Wei Zhang
- Corresponding authors: Yong Lu, Cancer Center, Weill Cornell Medicine, Houston Methodist Hospital, Houston, TX 77030, USA. E-mail: ; Wei Zhang, Department of Cancer Biology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel.: 336.713.7508; E-mail: ; Guangxu Jin, Department of Cancer Biology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel.: 336.713.7515; E-mail:
| | - Guangxu Jin
- Corresponding authors: Yong Lu, Cancer Center, Weill Cornell Medicine, Houston Methodist Hospital, Houston, TX 77030, USA. E-mail: ; Wei Zhang, Department of Cancer Biology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel.: 336.713.7508; E-mail: ; Guangxu Jin, Department of Cancer Biology, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA. Tel.: 336.713.7515; E-mail:
| |
Collapse
|
16
|
Wang RS, Lembo AJ, Kaptchuk TJ, Cheng V, Nee J, Iturrino J, Rao M, Loscalzo J, Silvester JA, Hall KT. Genomic Effects Associated With Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome. Front Pain Res 2022; 2:775386. [PMID: 35295415 PMCID: PMC8915627 DOI: 10.3389/fpain.2021.775386] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 11/15/2021] [Indexed: 12/12/2022] Open
Abstract
Background and Aims: Irritable bowel syndrome (IBS), a functional pain disorder of gut-brain interactions, is characterized by a high placebo response in randomized clinical trials (RCTs). Catechol-O-methyltransferase (COMT) rs4680, which encodes high-activity (val) or low-activity (met) enzyme variants, was previously associated with placebo response to sham-acupuncture in an IBS RCT. Examining COMT effects and identifying novel genomic factors that influence response to placebo pills is critical to identifying underlying mechanisms and predicting and managing placebos in RCTs. Methods: Participants with IBS (N = 188) were randomized to three placebo-related interventions, namely, double-blind placebo (DBP), open-label placebo (OLP), or simply trial enrollment without placebo treatment [no placebo (i.e., no pill) treatment control (NPC)], for 6 weeks. COMT rs4680, gene-set, and genome-wide suggestive (p < 10−5) loci effects on irritable bowel symptom severity score (IBS-SSS) across all participants were examined. Results: Participants with IBS homozygous for rs4680 met (met/met) had the greatest improvement across all arms, with significantly greater improvement compared to val/val in DBP (beta (SE), −89.4 (42.3); p = 0.04). Twelve genome-wide suggestive loci formed a gene regulatory network highly connected to EGR1, a transcription factor involved in placebo-related processes of learning, memory, and response to stress and reward. EGR1 gene expression in peripheral blood mononuclear cells (PBMC) was significantly reduced at the endpoint across all treatment arms (log fold-change, −0.15; p = 0.02). Gene-set enrichment analysis returned three genome-wide significant ontology terms (GO:0032968, GO:0070934, and GO:0070937) linked to transcription regulation and GO:0003918 associated with DNA topoisomerase regulation. Conclusion: These results suggest common molecular mechanisms in response to varying forms of placebo that may inform personalized IBS treatment and placebo response prediction. Clinical Trial Registration:ClinicalTrials.gov, Identifier: NCT0280224.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Department of Medicine, Brigham Women's Hospital, Boston, MA, United States
- Department of Medicine, Harvard Medical School, Boston, MA, United States
| | - Anthony J. Lembo
- Department of Medicine, Harvard Medical School, Boston, MA, United States
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, United States
| | - Ted J. Kaptchuk
- Program in Placebo Studies, Beth Israel Deaconess Medical Center, Boston, MA, United States
- Department of General Medicine Primary Care, Beth Israel Deaconess Medical Center, Boston, MA, United States
| | - Vivian Cheng
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, United States
| | - Judy Nee
- Department of Medicine, Harvard Medical School, Boston, MA, United States
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, United States
| | - Johanna Iturrino
- Department of Medicine, Harvard Medical School, Boston, MA, United States
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, United States
| | - Meenakshi Rao
- Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States
- Department of Pediatrics, Harvard Medical School, Boston, MA, United States
| | - Joseph Loscalzo
- Department of Medicine, Brigham Women's Hospital, Boston, MA, United States
- Department of Medicine, Harvard Medical School, Boston, MA, United States
| | - Jocelyn A. Silvester
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, United States
- Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States
- Department of Pediatrics, Harvard Medical School, Boston, MA, United States
- Celiac Disease Program, Boston Children's Hospital, Boston, MA, United States
| | - Kathryn T. Hall
- Department of Medicine, Brigham Women's Hospital, Boston, MA, United States
- Department of Medicine, Harvard Medical School, Boston, MA, United States
- Program in Placebo Studies, Beth Israel Deaconess Medical Center, Boston, MA, United States
- *Correspondence: Kathryn T. Hall
| |
Collapse
|
17
|
Anthony AK, Niu CY, Wang RS, Wieske J, Brown KW, Chajecki Z, Lynch WG, Ayyad Y, Barney J, Baumann T, Bazin D, Beceiro-Novo S, Boza J, Chen J, Cook KJ, Cortesi M, Ginter T, Mittig W, Pype A, Smith MK, Soto C, Sumithrarachchi C, Swaim J, Sweany S, Teh FCE, Tsang CY, Tsang MB, Watwood N, Wuosmaa AH. Beam particle identification and tagging of incompletely stripped heavy beams with HEIST. Rev Sci Instrum 2022; 93:013306. [PMID: 35104937 DOI: 10.1063/5.0068180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 12/15/2021] [Indexed: 06/14/2023]
Abstract
A challenge preventing successful inverse kinematics measurements with heavy nuclei that are not fully stripped is identifying and tagging the beam particles. For this purpose, the HEavy ISotope Tagger (HEIST) has been developed. HEIST utilizes two micro-channel plate timing detectors to measure the time-of-flight, a multi-sampling ion chamber to measure energy loss, and a high-purity germanium detector to identify isomer decays and calibrate the isotope identification system. HEIST has successfully identified 198Pb and other nearby nuclei at energies of about 75 MeV/A. In the experiment discussed, a typical cut containing 89% of all 198Pb80+ in the beam had a purity of 86%. We examine the issues of charge state contamination. The observed charge state populations of these ions are presented and, using an adjusted beam energy, are well described by the charge state model GLOBAL.
Collapse
Affiliation(s)
- A K Anthony
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Y Niu
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - R S Wang
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Wieske
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - K W Brown
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - Z Chajecki
- Department of Physics, Western Michigan University, Kalamazoo, Michigan 49008, USA
| | - W G Lynch
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - Y Ayyad
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Barney
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Baumann
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - D Bazin
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Beceiro-Novo
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Boza
- Department of Physics, Western Michigan University, Kalamazoo, Michigan 49008, USA
| | - J Chen
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - K J Cook
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - M Cortesi
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Ginter
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - W Mittig
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - A Pype
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - M K Smith
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Soto
- Department of Physics, Western Michigan University, Kalamazoo, Michigan 49008, USA
| | - C Sumithrarachchi
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - J Swaim
- Department of Physics, Western Michigan University, Kalamazoo, Michigan 49008, USA
| | - S Sweany
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - F C E Teh
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - C Y Tsang
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - M B Tsang
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - N Watwood
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - A H Wuosmaa
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269, USA
| |
Collapse
|
18
|
Alba GA, Samokhin AO, Wang RS, Zhang YY, Wertheim BM, Arons E, Greenfield EA, Lundberg Slingsby MH, Ceglowski JR, Haley KJ, Bowman FP, Yu YR, Haney JC, Eng G, Mitchell RN, Sheets A, Vargas SO, Seo S, Channick RN, Leary PJ, Rajagopal S, Loscalzo J, Battinelli EM, Maron BA. NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. Am J Respir Crit Care Med 2021; 203:1533-1545. [PMID: 33523764 PMCID: PMC8483217 DOI: 10.1164/rccm.202003-0719oc] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2020] [Accepted: 01/29/2021] [Indexed: 12/16/2022] Open
Abstract
Rationale: Data on the molecular mechanisms that regulate platelet-pulmonary endothelial adhesion under conditions of hypoxia are lacking, but may have important therapeutic implications. Objectives: To identify a hypoxia-sensitive, modifiable mediator of platelet-pulmonary artery endothelial cell adhesion and thrombotic remodeling. Methods: Network medicine was used to profile protein-protein interactions in hypoxia-treated human pulmonary artery endothelial cells. Data from liquid chromatography-mass spectrometry and microscale thermophoresis informed the development of a novel antibody (Ab) to inhibit platelet-endothelial adhesion, which was tested in cells from patients with chronic thromboembolic pulmonary hypertension (CTEPH) and three animal models in vivo. Measurements and Main Results: The protein NEDD9 was identified in the hypoxia thrombosome network in silico. Compared with normoxia, hypoxia (0.2% O2) for 24 hours increased HIF-1α (hypoxia-inducible factor-1α)-dependent NEDD9 upregulation in vitro. Increased NEDD9 was localized to the plasma-membrane surface of cells from control donors and patients with CTEPH. In endarterectomy specimens, NEDD9 colocalized with the platelet surface adhesion molecule P-selectin. Our custom-made anti-NEDD9 Ab targeted the NEDD9-P-selectin interaction and inhibited the adhesion of activated platelets to pulmonary artery endothelial cells from control donors in vitro and from patients with CTEPH ex vivo. Compared with control mice, platelet-pulmonary endothelial aggregates and pulmonary hypertension induced by ADP were decreased in NEDD9-/- mice or wild-type mice treated with the anti-NEDD9 Ab, which also decreased chronic pulmonary thromboembolic remodeling in vivo. Conclusions: The NEDD9-P-selectin protein-protein interaction is a modifiable target with which to inhibit platelet-pulmonary endothelial adhesion and thromboembolic vascular remodeling, with potential therapeutic implications for patients with disorders of increased hypoxia signaling pathways, including CTEPH.
Collapse
Affiliation(s)
- George A. Alba
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and
| | - Andriy O. Samokhin
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - Rui-Sheng Wang
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - Ying-Yi Zhang
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | | | - Elena Arons
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | | | | | | | | | - Frederick P. Bowman
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - Yen-Rei Yu
- Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
| | - John. C. Haney
- Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - George Eng
- Division of Pulmonary and Critical Care Medicine, Department of Medicine
| | | | - Anthony Sheets
- Division of Cardiovascular and Thoracic Surgery, Department of Surgery, and
| | - Sara O. Vargas
- Division of Cardiology, Department of Medicine, Duke University Medical Center, Duke University, Durham, North Carolina
| | - Sachiko Seo
- Department of Pathology, Boston Children’s Hospital, Boston, Massachusetts
| | - Richard N. Channick
- Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan
| | - Peter J. Leary
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, Los Angeles, California; and
| | - Sudarshan Rajagopal
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, Washington
| | - Joseph Loscalzo
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | | | - Bradley A. Maron
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| |
Collapse
|
19
|
Maron BA, Wang RS, Shevtsov S, Drakos SG, Arons E, Wever-Pinzon O, Huggins GS, Samokhin AO, Oldham WM, Aguib Y, Yacoub MH, Rowin EJ, Maron BJ, Maron MS, Loscalzo J. Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes. Nat Commun 2021; 12:873. [PMID: 33558530 PMCID: PMC7870822 DOI: 10.1038/s41467-021-21146-y] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 01/13/2021] [Indexed: 12/19/2022] Open
Abstract
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients. Here, myectomy tissue from patients with obstructive hypertrophic cardiomyopathy and heart failure is analyzed using RNA-Seq, and the results are used to develop individualized protein-protein interaction networks. From this approach, hypertrophic cardiomyopathy is distinguished from dilated cardiomyopathy based on the protein-protein interaction network pattern. Within the hypertrophic cardiomyopathy cohort, the patient-specific networks are variable in complexity, and enriched for 30 endophenotypes. The cardiac Janus kinase 2-Signal Transducer and Activator of Transcription 3-collagen 4A2 (JAK2-STAT3-COL4A2) expression profile informed by the networks was able to discriminate two hypertrophic cardiomyopathy patients with extreme fibrosis phenotypes. Patient-specific network features also associate with other important hypertrophic cardiomyopathy clinical phenotypes. These proof-of-concept findings introduce personalized protein-protein interaction networks (reticulotypes) for characterizing patient-specific pathobiology, thereby offering a direct strategy for advancing precision medicine.
Collapse
Affiliation(s)
- Bradley A Maron
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
| | - Rui-Sheng Wang
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Sergei Shevtsov
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Stavros G Drakos
- Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Elena Arons
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Omar Wever-Pinzon
- Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Gordon S Huggins
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Andriy O Samokhin
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - William M Oldham
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Yasmine Aguib
- Department of Cardiac Surgery, Imperial College of London, London, UK
- The Magdi Yacoub Heart Center, Aswan, Egypt
| | - Magdi H Yacoub
- Department of Cardiac Surgery, Imperial College of London, London, UK
- The Magdi Yacoub Heart Center, Aswan, Egypt
| | - Ethan J Rowin
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Barry J Maron
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Martin S Maron
- Hypertrophic Cardiomyopathy Center, Cardiology Division, Tufts Medical Center, Boston, MA, USA
| | - Joseph Loscalzo
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| |
Collapse
|
20
|
Paci P, Fiscon G, Conte F, Wang RS, Farina L, Loscalzo J. Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery. NPJ Syst Biol Appl 2021; 7:3. [PMID: 33479222 PMCID: PMC7819998 DOI: 10.1038/s41540-020-00168-0] [Citation(s) in RCA: 49] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Accepted: 10/19/2020] [Indexed: 01/29/2023] Open
Abstract
In this study, we integrate the outcomes of co-expression network analysis with the human interactome network to predict novel putative disease genes and modules. We first apply the SWItch Miner (SWIM) methodology, which predicts important (switch) genes within the co-expression network that regulate disease state transitions, then map them to the human protein-protein interaction network (PPI, or interactome) to predict novel disease-disease relationships (i.e., a SWIM-informed diseasome). Although the relevance of switch genes to an observed phenotype has been recently assessed, their performance at the system or network level constitutes a new, potentially fascinating territory yet to be explored. Quantifying the interplay between switch genes and human diseases in the interactome network, we found that switch genes associated with specific disorders are closer to each other than to other nodes in the network, and tend to form localized connected subnetworks. These subnetworks overlap between similar diseases and are situated in different neighborhoods for pathologically distinct phenotypes, consistent with the well-known topological proximity property of disease genes. These findings allow us to demonstrate how SWIM-based correlation network analysis can serve as a useful tool for efficient screening of potentially new disease gene associations. When integrated with an interactome-based network analysis, it not only identifies novel candidate disease genes, but also may offer testable hypotheses by which to elucidate the molecular underpinnings of human disease and reveal commonalities between seemingly unrelated diseases.
Collapse
Affiliation(s)
- Paola Paci
- Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy.
| | - Giulia Fiscon
- Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy
- Fondazione per la Medicina Personalizzata, Via Goffredo Mameli, 3/1 Genova, Italy
| | - Federica Conte
- Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy
| | - Rui-Sheng Wang
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| | - Lorenzo Farina
- Department of Computer, Control and Management Engineering, Sapienza University of Rome, Rome, Italy
| | - Joseph Loscalzo
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| |
Collapse
|
21
|
Qi Y, Toyooka T, Nie J, Ohta H, Koda S, Wang RS. Comparative γ-H2AX analysis for assessment of the genotoxicity of six aromatic amines implicated in bladder cancer in human urothelial cell line. Toxicol In Vitro 2020; 66:104880. [PMID: 32387221 DOI: 10.1016/j.tiv.2020.104880] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2019] [Revised: 03/04/2020] [Accepted: 04/27/2020] [Indexed: 11/25/2022]
Abstract
Recently, it was reported that ten cases of bladder cancer occurred among employees, who handled several kinds of aromatic amines, at a Japanese chemical plant. The common aromatic amines were identified as ortho-toluidine, para-toluidine, aniline, ortho-chloroaniline, ortho-anisidine, and 2,4-dimethylaniline. All of these aromatic amines, except ortho-chloroaniline, have been found to be carcinogenic in animals and/or humans. Genotoxic events are known to be crucial steps in the initiation of cancer; information on the genotoxicity of these aromatic amines is insufficient and consistent results have not been obtained. In this study, we examined the genotoxicity of the six different aromatic amines associated with bladder cancer by assessing phosphorylated histone H2AX (γ-H2AX) in a cultured human urothelial cell line, 1T1. We showed that all six aromatic amines generated γ-H2AX. In addition, the γ-H2AX-inducing potential of these six aromatic amines was distinctly different; ortho-chloroaniline and 2,4-dimethylaniline showed particularly high potential, followed by ortho-toluidine, ortho-anisidine, para-toluidine ≒ aniline. The findings of this study may provide important information for the risk assessment of chemicals and for interpreting epidemiological studies on occupational bladder cancer.
Collapse
Affiliation(s)
- Yonggang Qi
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China; Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Kawasaki, Japan; Department of Environmental, Occupational Health and Toxicology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan
| | - Tatsushi Toyooka
- Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Kawasaki, Japan.
| | - Jisheng Nie
- Department of Occupational Health, School of Public Health, Shanxi Medical University, Taiyuan, China
| | - Hisayoshi Ohta
- Department of Environmental, Occupational Health and Toxicology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Japan
| | - Shigeki Koda
- Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Rui-Sheng Wang
- Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Kawasaki, Japan
| |
Collapse
|
22
|
Suzuki T, Miura N, Hojo R, Yanagiba Y, Suda M, Hasegawa T, Miyagawa M, Wang RS. Correction to: Genotoxicity assessment of titanium dioxide nanoparticle accumulation of 90 days in the liver of gpt delta transgenic mice. Genes Environ 2020; 42:10. [PMID: 32161627 PMCID: PMC7053085 DOI: 10.1186/s41021-020-00151-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
[This corrects the article DOI: 10.1186/s41021-020-0146-3.].
Collapse
Affiliation(s)
- Tetsuya Suzuki
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan.,2Present address: Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553 Japan
| | - Nobuhiko Miura
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan.,3Present Address: Department of Health Science, Yokohama University of Pharmacy, Yokohama, 245-0066 Japan
| | - Rieko Hojo
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| | - Yukie Yanagiba
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| | - Megumi Suda
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| | - Tatsuya Hasegawa
- 4Division of Human Environmental Science, Mount Fuji Research Institute, Yamanashi Prefectural Government, 5597-1 Kenmarubi, Kamiyoshida, Fujiyoshida, Yamanashi, 403-0005 Japan
| | - Muneyuki Miyagawa
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan.,5Present Address: Department of Sport and Medical Science, Faculty of Medical Technology, Teikyo University, Hachioji, Tokyo, 192-0835 Japan
| | - Rui-Sheng Wang
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| |
Collapse
|
23
|
Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, Fei G, Ren L, Zhou YW, Liu L. Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi 2020; 36:21-23. [PMID: 32198987 DOI: 10.12116/j.issn.1004-5619.2020.01.005] [Citation(s) in RCA: 134] [Impact Index Per Article: 33.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Indexed: 12/14/2022]
Abstract
Abstract
Collapse
Affiliation(s)
- Q Liu
- Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - R S Wang
- Chongxin Judicial Expertise Center,Wuhan 43041 5,China
| | - G Q Qu
- Chongxin Judicial Expertise Center,Wuhan 43041 5,China
| | - Y Y Wang
- Chongxin Judicial Expertise Center,Wuhan 43041 5,China
| | - P Liu
- Chongxin Judicial Expertise Center,Wuhan 43041 5,China
| | - Y Z Zhu
- Chongxin Judicial Expertise Center,Wuhan 43041 5,China
| | - G Fei
- Shanghai Police College, Shanghai 200120, China
| | - L Ren
- Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - Y W Zhou
- Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - L Liu
- Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| |
Collapse
|
24
|
Lin L, Suda M, Xu C, Zhang Y, Yanagiba Y, Nie J, Nakajima T, Weng Z, Wang RS. Aldehyde dehydrogenase 2 deficiency significantly exacerbates tert-butyl alcohol-induced toxicity in mice. J Appl Toxicol 2020; 40:979-990. [PMID: 32059264 DOI: 10.1002/jat.3957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 01/22/2020] [Accepted: 01/24/2020] [Indexed: 11/09/2022]
Abstract
Owing to the use of ethyl tert-butyl ether (ETBE) as a fuel additive, the possible adverse effects of ETBE exposure have become a public concern. Our previous study showed that ETBE-induced toxicity in aldehyde dehydrogenase 2 (Aldh2) gene knockout (KO) mice was caused by its primary metabolite acetaldehyde, which was toxic. However, it is unclear whether tert-butyl alcohol (TBA), another main metabolite of ETBE, plays a role in ETBE-induced toxicity. To investigate this relationship, we analyzed the changes of TBA concentrations in tissues after ETBE exposure, and then evaluated the toxicity after direct TBA treatment in both KO and wild-type (WT) mice. An exposure to 500 ppm ETBE via inhalation resulted in the formation of its three metabolites, TBA, 2-methyl-1,2-propanediol and ethanol, whose concentrations in the liver, brain, fat and testis of male KO mice were significantly higher than the corresponding concentrations observed in male WT mice. Direct treatment to TBA (20 mg/mL of drinking water) caused significant changes in relative organ weights and histopathology, and increased levels of genetic damages in both types of mice. These toxic effects were also seen in KO mice exposed to a lower concentration of TBA (5 mg/mL), which was associated with increased oxidative stress in serum (reduced glutathione and reduced glutathione/oxidized glutathione ratio decreased). Our findings indicate that ALDH2 is involved in the metabolism of ETBE and TBA, and ALDH2 deficiency could greatly increase the sensitivity to TBA-induced toxicity.
Collapse
Affiliation(s)
- Liping Lin
- Department of Clinical Laboratory, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China
| | - Megumi Suda
- Japan National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Chenlan Xu
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
| | - Yuehan Zhang
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
| | - Yukie Yanagiba
- Japan National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Jisheng Nie
- School of Public Health, Shanxi Medical University, Taiyuan, China
| | - Tamie Nakajima
- College of Life and Health Sciences, Chubu University, Nagoya, Japan
| | - Zuquan Weng
- Japan National Institute of Occupational Safety and Health, Kawasaki, Japan.,College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
| | - Rui-Sheng Wang
- Japan National Institute of Occupational Safety and Health, Kawasaki, Japan
| |
Collapse
|
25
|
Suzuki T, Miura N, Hojo R, Yanagiba Y, Suda M, Hasegawa T, Miyagawa M, Wang RS. Genotoxicity assessment of titanium dioxide nanoparticle accumulation of 90 days in the liver of gpt delta transgenic mice. Genes Environ 2020; 42:7. [PMID: 32071618 PMCID: PMC7011542 DOI: 10.1186/s41021-020-0146-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Accepted: 01/27/2020] [Indexed: 01/15/2023] Open
Abstract
Backgound A variety of in vivo and in vitro studies to assess the genotoxicity of titanium dioxide nanoparticles (TiO2 NPs) have been reported, but the results are inconsistent. Recently, we reported that TiO2 NPs exhibit no genotoxic effects in the liver and erythrocytes during a relatively brief period following intravenous injection into mice. However, there is no information about long-term genotoxicity due to TiO2 NP accumulation in tissues. In this study, we investigated the long-term mutagenic effects of TiO2 NPs and the localization of residual TiO2 NPs in mouse liver after multiple intravenous injections. Results Male gpt delta C57BL/6 J mice were administered with various doses of TiO2 NPs weekly for 4 consecutive weeks. The long-term mutagenic effects on the liver were analyzed using gpt and Spi− mutation assays 90 days after the final injection. We also quantified the amount of titanium in the liver using inductively coupled plasma mass spectrometry and observed the localization of TiO2 NPs in the liver using transmission electron microscopy. Although TiO2 NPs were found in the liver cells, the gpt and Spi− mutation frequencies in the liver were not significantly increased by the TiO2 NP administration. Conclusions These results clearly show that TiO2 NPs have no mutagenic effects on the liver, even though the particles remain in the liver long-term.
Collapse
Affiliation(s)
- Tetsuya Suzuki
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan.,2Present address: Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553 Japan
| | - Nobuhiko Miura
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan.,3Present Address: Department of Health Science, Yokohama University of Pharmacy, Yokohama, 245-0066 Japan
| | - Rieko Hojo
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| | - Yukie Yanagiba
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| | - Megumi Suda
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| | - Tatsuya Hasegawa
- 4Division of Human Environmental Science, Mount Fuji Research Institute, Yamanashi Prefectural Government, 5597-1 Kenmarubi, Kamiyoshida, Fujiyoshida, Yamanashi, 403-0005 Japan
| | - Muneyuki Miyagawa
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan.,5Present Address: Department of Sport and Medical Science, Faculty of Medical Technology, Teikyo University, Hachioji, Tokyo, 192-0835 Japan
| | - Rui-Sheng Wang
- 1Division of Industrial Toxicology and Health Effects Research, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-ku, Kawasaki, Kanagawa 214-8585 Japan
| |
Collapse
|
26
|
Frid MG, McKeon BA, Thurman JM, Maron BA, Li M, Zhang H, Kumar S, Sullivan T, Laskowsky J, Fini MA, Hu S, Tuder RM, Gandjeva A, Wilkins MR, Rhodes CJ, Ghataorhe P, Leopold JA, Wang RS, Holers VM, Stenmark KR. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med 2020; 201:224-239. [PMID: 31545648 PMCID: PMC6961733 DOI: 10.1164/rccm.201903-0591oc] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Accepted: 09/20/2019] [Indexed: 01/18/2023] Open
Abstract
Rationale: Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder in which inflammation and immunity have emerged as critical early pathogenic elements. Although proinflammatory processes in PH and pulmonary arterial hypertension (PAH) are the focus of extensive investigation, the initiating mechanisms remain elusive.Objectives: We tested whether activation of the complement cascade is critical in regulating proinflammatory and pro-proliferative processes in the initiation of experimental hypoxic PH and can serve as a prognostic biomarker of outcome in human PAH.Methods: We used immunostaining of lung tissues from experimental PH models and patients with PAH, analyses of genetic murine models lacking specific complement components or circulating immunoglobulins, cultured human pulmonary adventitial fibroblasts, and network medicine analysis of a biomarker risk panel from plasma of patients with PAH.Measurements and Main Results: Pulmonary perivascular-specific activation of the complement cascade was identified as a consistent critical determinant of PH and PAH in experimental animal models and humans. In experimental hypoxic PH, proinflammatory and pro-proliferative responses were dependent on complement (alternative pathway and component 5), and immunoglobulins, particularly IgG, were critical for activation of the complement cascade. We identified Csf2/GM-CSF as a primary complement-dependent inflammatory mediator. Furthermore, using network medicine analysis of a biomarker risk panel from plasma of patients with PAH, we demonstrated that complement signaling can serve as a prognostic factor for clinical outcome in PAH.Conclusions: This study establishes immunoglobulin-driven dysregulated complement activation as a critical pathobiological mechanism regulating proinflammatory and pro-proliferative processes in the initiation of experimental hypoxic PH and demonstrates complement signaling as a critical determinant of clinical outcome in PAH.
Collapse
Affiliation(s)
- Maria G. Frid
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | - B. Alexandre McKeon
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | | | - Bradley A. Maron
- Division of Cardiovascular Medicine, Department of Medicine, School of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| | - Min Li
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | - Hui Zhang
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | - Sushil Kumar
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | - Timothy Sullivan
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | | | - Mehdi A. Fini
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | - Samantha Hu
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| | - Rubin M. Tuder
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and
| | - Aneta Gandjeva
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and
| | - Martin R. Wilkins
- Department of Medicine and National Heart and Lung Institute, Imperial College London, London, United Kingdom; and
| | - Christopher J. Rhodes
- Department of Medicine and National Heart and Lung Institute, Imperial College London, London, United Kingdom; and
| | - Pavandeep Ghataorhe
- Department of Medicine and National Heart and Lung Institute, Imperial College London, London, United Kingdom; and
| | - Jane A. Leopold
- Division of Cardiovascular Medicine, Department of Medicine, School of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
| | - Rui-Sheng Wang
- Channing Division of Network Medicine, Department of Medicine, School of Medicine, Brigham Health Brigham and Women’s Hospital, Boston, Massachusetts
| | - V. Michael Holers
- Division of Rheumatology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado
| | - Kurt R. Stenmark
- Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine
| |
Collapse
|
27
|
Wang RS, Croteau-Chonka DC, Silverman EK, Loscalzo J, Weiss ST, Hall KT. Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma. Clin Pharmacol Ther 2019; 106:1261-1267. [PMID: 31557306 DOI: 10.1002/cpt.1646] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Accepted: 09/21/2019] [Indexed: 12/24/2022]
Abstract
Genetic variation may differentially modify drug and placebo treatment effects in randomized clinical trials. In asthma, although lung function and asthma control improvements are commonplace with placebo, pharmacogenomics of placebo vs. drug response remains unexamined. In a genomewide association study of subjective and objective outcomes with placebo treatment in Childhood Asthma Management Program of nedocromil/budesonide vs. placebo (N = 604), effect estimates for lead single nucleotide polymorphisms (SNPs) were compared across arms. The coughing/wheezing lead SNP, rs2392165 (β = 0.94; P = 1.10E-07) mapped to BBS9, a gene implicated in lung development that contains a lung function expression quantitative trait locus. The effect was attenuated with budesonide (Pinteraction = 1.48E-07), but not nedocromil (Pinteraction = 0.06). The lead forced vital capacity SNP, rs12930749 (β = -5.80; P = 1.47E-06), mapped to KIAA0556, a locus genomewide associated with respiratory diseases. The rs12930749 effect was attenuated with budesonide (Pinteraction = 1.32E-02) and nedocromil (Pinteraction = 1.09E-02). Pharmacogenomic analysis revealed differential effects with placebo and drug treatment that could potentially guide precision drug development in asthma.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Damien C Croteau-Chonka
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Edwin K Silverman
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - J Loscalzo
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Scott T Weiss
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Kathryn T Hall
- Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
28
|
Ohta H, Qi Y, Ohba K, Toyooka T, Wang RS. Role of metallothionein-like cadmium-binding protein (MTLCdBP) in the protective mechanism against cadmium toxicity in the testis. Ind Health 2019; 57:570-579. [PMID: 30606898 PMCID: PMC6783288 DOI: 10.2486/indhealth.2018-0177] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Accepted: 12/20/2018] [Indexed: 06/09/2023]
Abstract
The role of metallothionein (MT)-like cadmium (Cd) binding protein (MTLCdBP) in protecting the testes against Cd toxicity was examined. In the acute Cd exposure treatment, cadmium chloride was intraperitoneally injected at 2 mg Cd/kg to Wistar male rats. In the chronic Cd toxicity treatments, 20 mg Cd/kg/d was orally administered for 5 d a week for 5, 10, and 15 wk. MT (-I,-II) and MTLCdBP were measured using ELISA and Cd-Hem methods, respectively. Testicular tissues were immunostained with antibodies of MT-I,-II, MT-III, and MTLCdBP. Expression of HO1, OGG, iNOS, COX2, and p53 was measured by RT-PCR. Cd concentration in the testis increased dose-dependently in response to Cd exposure. MTLCdBP concentration increased markedly with increasing Cd accumulation. Significant increases in expression of iNOS, HO1, COX2, and OGG1 were observed in the acute exposure treatment. In the chronic oral administration group, expression of MT-I, MT-II, MT-III, iNOS, HO1, and COX2 did not change. Positive immunostaining of MTLCdBP was observed in testicular interstitial tissue. In the testis protected from Cd toxicity, MTLCdBP induction increased significantly with increasing Cd accumulation. Our results suggest that MTLCdBP plays an important role in protecting the testis against Cd toxicity.
Collapse
Affiliation(s)
- Hisayoshi Ohta
- Department of Environmental, Occupational Health and Toxicology, Graduate School of Medical Sciences, Kitasato University, Japan
- 2Department of Environmental, Occupational Health and Toxicology, School of Allied Health Sciences, Kitasato University, Japan
| | - Yonggang Qi
- Department of Environmental, Occupational Health and Toxicology, Graduate School of Medical Sciences, Kitasato University, Japan
| | - Kenichi Ohba
- 2Department of Environmental, Occupational Health and Toxicology, School of Allied Health Sciences, Kitasato University, Japan
| | - Tatsushi Toyooka
- 3Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Japan
| | - Rui-Sheng Wang
- Department of Environmental, Occupational Health and Toxicology, Graduate School of Medical Sciences, Kitasato University, Japan
- 3Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Japan
| |
Collapse
|
29
|
Itoh H, Wang RS, Maki S, Niu Q, Shang H, Su Y, Weng Z, Saito H, Miura N, Takahashi M. Effects of work schedule and period of exposure on changes in urinary chromium and nickel excretion among rotating shift workers in a stainless-steel plant. Chronobiol Int 2019; 36:1439-1446. [PMID: 31368363 DOI: 10.1080/07420528.2019.1645159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We investigated the association between the period of exposure and changes in urinary excretion of chromium and nickel among rotating shift workers in a stainless-steel plant. The study participants were composed of two groups: the workers who were occupationally exposed to metals ("exposed group") and those who were not occupationally exposed to metals ("unexposed group"). The exposed and unexposed groups consisted of 56 and 40 male rotating shift workers, respectively. Urine samples were collected immediately before and immediately after the day shift, evening shift, and night shift. Urinary chromium and nickel were measured using inductively coupled plasma mass spectrometry. To correct for variations in urine dilution, urinary metal concentrations were expressed as a ratio to urinary creatinine concentration. In the exposed group, post-shift urinary excretion of chromium was significantly higher than pre-shift excretion. However, although urinary chromium excretion clearly increased after the day and night shift [63% (p < .0001) and 87% (p < .0001), respectively], urinary chromium excretion after the evening shift was only slightly higher than that measured before the evening shift (8%, p = .028). Similar patterns were found for urinary nickel excretion (p = .0001, 0.20, and 0.18 for the day, evening, and night shifts, respectively). Non-uniform urinary excretion of metals between the day shift, evening shift, and night shift were observed in the exposed group; specifically, urinary metal excretion increased only slightly during the evening shift. In the unexposed group, no significant increase or decrease was found in median urinary chromium or nickel excretion (p= .63-0.87). Work shift-specific permissible exposure level would be necessary.
Collapse
Affiliation(s)
- Hiroaki Itoh
- Department of Epidemiology and Environmental Health, Juntendo University Faculty of Medicine , Tokyo , Japan.,Graduate School of Environment and Information Sciences, Yokohama National University , Yokohama , Japan.,National Institute of Occupational Safety and Health , Tama-ku, Kawasaki , Japan
| | - Rui-Sheng Wang
- National Institute of Occupational Safety and Health , Tama-ku, Kawasaki , Japan
| | - Syou Maki
- National Institute of Occupational Safety and Health , Tama-ku, Kawasaki , Japan.,Laboratory of Molecular Chemistry, Faculty of Pharmacy, Osaka Ohtani University , Osaka Pref , Japan
| | - Qiao Niu
- Department of Occupational and Environmental Health, Shanxi Medical University , Taiyuan , China
| | - Huizhen Shang
- Center for Disease Control and Prevention, Taiyuan Steel and Iron Limited Co , Taiyuan , China
| | - Yougong Su
- General Hospital, Taiyuan Steel and Iron Limited Co , Taiyuan , China
| | - Zuquan Weng
- National Institute of Occupational Safety and Health , Tama-ku, Kawasaki , Japan.,College of Biological Science and Engineering, Fuzhou University , Fuzhou , China
| | - Hiroyuki Saito
- National Institute of Occupational Safety and Health , Tama-ku, Kawasaki , Japan
| | - Nobuhiko Miura
- National Institute of Occupational Safety and Health , Tama-ku, Kawasaki , Japan
| | - Masaya Takahashi
- National Institute of Occupational Safety and Health , Tama-ku, Kawasaki , Japan
| |
Collapse
|
30
|
Wang RS, Zhang ZL, Chen YT, Xia YL, Lin XM, Zhang JS, Yan MZ. [Transformation and attribution of drug properties in Galla Chinesis fermented Baiyaojian based on cold and heat syndrome rats]. Zhongguo Zhong Yao Za Zhi 2019; 44:2084-2089. [PMID: 31355565 DOI: 10.19540/j.cnki.cjcmm.20181221.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
To reveal the transformation and attribution of drug properties in Galla Chinesis fermented Baiyaojian by studying the effect of Galla Chinesis and Baiyaojian on cold and heat syndrome rats. Euthyrox was used to induce the hyperthyrosis model,ice water stimulation was used to induce the cold syndrome model,and different concentrations of Galla Chinesis and Baiyaojian water decoction were administrated by gavage for 15 d continuously. Symptom indexes were evaluated,content of pyruvic acid( PA),ATPase activity in liver and contents of DA,T4,cAMP,5-HT,NE,17-OHCS,TRH and TSH in serum were assayed by enzyme linked immunosorbent assay and spectrophotometry. The rectal temperature,water consumption and body weight of heat syndrome rats in model group were increased,cAMP,NE,17-OHCS,TRH and PA were increased,TSH,Na-K ATPase and Ca-Mg ATPase were increased significantly( P<0. 01),while 5-HT was decreased,compared with those of the blank group( P< 0. 05),the contents of T4,DA,NE,TSH,TRH,cAMP and 17-OHCS were decreased significantly( P<0. 01),PA and Ca-Mg ATPase in WG and BG groups were decreased compared with those of the model group( P<0. 05),and the Galla Chinesis content of WG group was lower than that of BG group,while the contents of 5-HT in WG and BG groups were increased,and the Galla Chinesis content of WG group was higher than that of BG group,with no significant difference of viscera index between heat syndrome rats in blank group,model group and drug groups. The rectal temperature,water consumption and body weight of cold syndrome rats in model group were decreased,DA,T4,cAMP,NE,17-OHCS,TRH,TSH,PA,Na-K ATPase and Ca-Mg ATPase of rats in model group were decreased,whereas 5-HT was increased compared with those of the blank group( P<0. 05),the indexes of heart,lung and kidney were significantly higher than those in the blank group( P<0. 05). Both Galla Chinesis and Baiyaojian can significantly alleviate the symptoms of heat syndrome rats caused by levothyroxine sodium. Galla Chinesis has a better effect than Baiyaojian,but cannot alleviate the symptoms of cold syndrome caused by ice water stimulation,suggestting that the decoction of Galla Chinesis and Baiyaojian are both cold,but Galla Chinesis is colder than Baiyaojian. Cold property in Galla Chinesis fermented Baiyaojian can be relieved. In clinical application,the property of " slight cold" is more accurate than " neutral property" for Baiyaojian.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Henan University of Chinese Medicine Zhengzhou 450008,China
| | | | - Yi-Tian Chen
- Henan University of Chinese Medicine Zhengzhou 450008,China
| | - Yun-Ling Xia
- Henan University of Chinese Medicine Zhengzhou 450008,China
| | - Xiu-Min Lin
- Henan University of Chinese Medicine Zhengzhou 450008,China
| | | | - Meng-Zhen Yan
- Henan University of Chinese Medicine Zhengzhou 450008,China
| |
Collapse
|
31
|
Jin G, Xue G, Wang RS, Wu LY, Miller L, Lu Y, Zhang W. Abstract LB-218: High-dimensional modeling of single-cell-based CD8+ T cell exhaustion predicts response to immune checkpoint blockade. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-lb-218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION Accurate prediction of response to existing immune checkpoint blockade (ICB) and development of more efficacious ICB strategies are needed for cancer immunotherapy. The single-cell-level characterization of tumor-infiltrating CD8+ T lymphocytes (TILs) has presented new opportunities. However, the phenotypic variability of TILs, including tumor-specificity and CD8+ TIL exhaustion that regulate response to ICB, is poorly understood. Computationally modeling a large number of CD8+ TILs with high-dimensional T cell functional markers can link high-dimensional single-cell data with fundemental T cell functionalities.
METHODS Here we develop a computational method (called HD-scMed) to predict response to ICB at the single-cell level. Our high-dimensional single-cell method, HD-scMed, models the phenotypic variability of CD8+ TILs directly within the original high-dimensional expression space, defined by k-dimensional exhaustion markers and other T cell functional markers. Within the high-dimensional expression space, HD-scMed identifies Pareto-optimal Frontier (PF) TILs representing a subset of exhausted TILs, by a mathematical model, Pareto Optimization. A quantitative criterion, D-value, defined as the Euclidean distance from PF TILs to the baseline TILs excluded by the PF, is used to indicate the extent to which the PF TILs are exhausted.
RESULTS D-value accurately predicts clinical response to the ICB, i.e., αPD-1, αCTLA-4, and αPD-1+αCTLA-4, with performance of AUC=100% by single-cell flow cytometry (CyTOF) data with 101,401 CD8+ TILs from human tumors after ICBs, and AUC=95% and 86% by single-cell RNA-seq (scRNA-seq) data including 9,405 CD8+ TILs from human tumors before and after ICBs, respectively. Mechanistically, “D-high” TILs are associated with high tumor-specificity, enhanced exhaustion, and inactivated effector and cytotoxic signatures in non-responders; whereas “D-low” TILs are enriched in responders demonstrating tumor-specific T cells with T cell activation and cytolytic effector T cell signatures. We also observed “D negative” bystander T cells irrelevant to response. Notably, LAG3 shows significantly higher contribution to TIL D values in non-responders than responders. To reverse the functionality of the LAG3-high TILs after receiving αPD-1+αCTLA-4, we tested the effects of αLAG3 with αPD-1+αCTLA-4 in murine tumor models. Remarkably, the combination, αLAG3+αPD-1+αCTLA-4, showed extraordinary antitumor efficacy in eradicating advanced tumors, which was associated with burst GZMBhi TIL populations; whereas αPD-1+αCTLA-4 or αPD-1+αCTLA-4 plus other ICBs as control showed only moderate inhibition of tumor growth.
CONCLUSION Our study has important implications for cancer immunotherapy regarding both accurate prediction of ICB response and development of better strategies to reverse existing ICB resistance.
Citation Format: Guangxu Jin, Gang Xue, Rui-Sheng Wang, Ling-Yun Wu, Lance Miller, Yong Lu, Wei Zhang. High-dimensional modeling of single-cell-based CD8+ T cell exhaustion predicts response to immune checkpoint blockade [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-218.
Collapse
Affiliation(s)
- Guangxu Jin
- 1Wake Forest School of Medicine, Winston-Salem, NC
| | - Gang Xue
- 1Wake Forest School of Medicine, Winston-Salem, NC
| | | | - Ling-Yun Wu
- 3Chinese Academy of Sciences, Beijing, China
| | - Lance Miller
- 1Wake Forest School of Medicine, Winston-Salem, NC
| | - Yong Lu
- 1Wake Forest School of Medicine, Winston-Salem, NC
| | - Wei Zhang
- 1Wake Forest School of Medicine, Winston-Salem, NC
| |
Collapse
|
32
|
Musri MM, Coll-Bonfill N, Maron BA, Peinado VI, Wang RS, Altirriba J, Blanco I, Oldham WM, Tura-Ceide O, García-Lucio J, de la Cruz-Thea B, Meister G, Loscalzo J, Barberà JA. MicroRNA Dysregulation in Pulmonary Arteries from Chronic Obstructive Pulmonary Disease. Relationships with Vascular Remodeling. Am J Respir Cell Mol Biol 2019; 59:490-499. [PMID: 29757677 DOI: 10.1165/rcmb.2017-0040oc] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Pulmonary vascular remodeling is an angiogenic-related process involving changes in smooth muscle cell (SMC) homeostasis, which is frequently observed in chronic obstructive pulmonary disease (COPD). MicroRNAs (miRNAs) are small, noncoding RNAs that regulate mRNA expression levels of many genes, leading to the manifestation of cell identity and specific cellular phenotypes. Here, we evaluate the miRNA expression profiles of pulmonary arteries (PAs) of patients with COPD and its relationship with the regulation of SMC phenotypic change. miRNA expression profiles from PAs of 12 patients with COPD, 9 smokers with normal lung function (SK), and 7 nonsmokers (NS) were analyzed using TaqMan Low-Density Arrays. In patients with COPD, expression levels of miR-98, miR-139-5p, miR-146b-5p, and miR-451 were upregulated, as compared with NS. In contrast, miR-197, miR-204, miR-485-3p, and miR-627 were downregulated. miRNA-197 expression correlated with both airflow obstruction and PA intimal enlargement. In an in vitro model of SMC differentiation, miR-197 expression was associated with an SMC contractile phenotype. miR-197 inhibition blocked the acquisition of contractile markers in SMCs and promoted a proliferative/migratory phenotype measured by both cell cycle analysis and wound-healing assay. Using luciferase assays, Western blot, and quantitative PCR, we confirmed that miR-197 targets the transcription factor E2F1. In PAs from patients with COPD, levels of E2F1 were increased as compared with NS. In PAs of patients with COPD, remodeling of the vessel wall is associated with downregulation of miR-197, which regulates SMC phenotype. The effect of miR-197 on PAs might be mediated, at least in part, by the key proproliferative factor, E2F1.
Collapse
Affiliation(s)
- Melina M Musri
- 1 Department of Pulmonary Medicine, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, University of Barcelona, Barcelona, Spain.,2 Instituto de Investigación Médica Mercedes y Martín Ferreyra, Consejo Nacional de Investigaciones Científicas y Técnicas (INIMEC-CONICET), Universidad Nacional de Córdoba, Cátedra de Genética, Departamento de Fisiología, Facultad de Ciencias Exactas Físicas y Naturales (FCEFyN), Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Núria Coll-Bonfill
- 1 Department of Pulmonary Medicine, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, University of Barcelona, Barcelona, Spain.,3 Biomedical Research Networking Center for Respiratory Diseases, Madrid, Spain
| | - Bradley A Maron
- 4 Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
| | - Víctor I Peinado
- 1 Department of Pulmonary Medicine, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, University of Barcelona, Barcelona, Spain.,3 Biomedical Research Networking Center for Respiratory Diseases, Madrid, Spain
| | - Rui-Sheng Wang
- 4 Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
| | - Jordi Altirriba
- 5 Laboratory of Metabolism, Department of Internal Medicine Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Isabel Blanco
- 1 Department of Pulmonary Medicine, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, University of Barcelona, Barcelona, Spain.,3 Biomedical Research Networking Center for Respiratory Diseases, Madrid, Spain
| | - William M Oldham
- 6 Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and
| | - Olga Tura-Ceide
- 1 Department of Pulmonary Medicine, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, University of Barcelona, Barcelona, Spain.,3 Biomedical Research Networking Center for Respiratory Diseases, Madrid, Spain
| | - Jessica García-Lucio
- 1 Department of Pulmonary Medicine, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, University of Barcelona, Barcelona, Spain
| | - Benjamin de la Cruz-Thea
- 2 Instituto de Investigación Médica Mercedes y Martín Ferreyra, Consejo Nacional de Investigaciones Científicas y Técnicas (INIMEC-CONICET), Universidad Nacional de Córdoba, Cátedra de Genética, Departamento de Fisiología, Facultad de Ciencias Exactas Físicas y Naturales (FCEFyN), Universidad Nacional de Córdoba, Córdoba, Argentina
| | - Gunter Meister
- 7 Biochemistry Center Regensburg, Laboratory for RNA Biology, University of Regensburg, Regensburg, Germany
| | - Joseph Loscalzo
- 4 Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
| | - Joan A Barberà
- 1 Department of Pulmonary Medicine, Hospital Clínic, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, University of Barcelona, Barcelona, Spain.,3 Biomedical Research Networking Center for Respiratory Diseases, Madrid, Spain
| |
Collapse
|
33
|
Weng Z, Shi Y, Suda M, Yanagiba Y, Kawamoto T, Nakajima T, Wang RS. Inhalation exposure to low levels of ethyl tertiary butyl ether: Its genetic effects were significantly modified by ALDH2 activity. Environ Mol Mutagen 2019; 60:145-153. [PMID: 30474146 DOI: 10.1002/em.22256] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Revised: 09/26/2018] [Accepted: 09/30/2018] [Indexed: 06/09/2023]
Abstract
Previous experiments showed that high concentrations of ethyl tertiary butyl ether (ETBE) exposure (500-5,000 ppm) significantly resulted in DNA damages in aldehyde dehydrogenase 2 (Aldh2) knockout (KO) mice. This study was aimed to verify the genotoxic effects in three genetic types, Aldh2 KO, heterogeneous (HT), and wild type (WT), of mice exposed to lower concentrations of ETBE (50-500 ppm) by inhalation. Histopathology assessments in the livers, measurements of genotoxic biomarkers in blood and livers, and urinary 8-hydroxydeoxyguanosion (8-OH-dG) for the oxidative DNA damage of whole body were performed. Significant histopathological changes and DNA strand breaks both in hepatocytes and leukocytes were found in HT and KO male mice exposed to ≥200 ppm ETBE, but not in 50 ppm ETBE. 8-OH-dG levels either in liver or urine were higher in the HT and KO male mice exposed to ≥200 ppm ETBE. The pathological and genetic effects of ETBE were almost at the same extents for HT and KO mice. Thus, 50 ppm could be the no observed adverse effect level for ETBE in HT and KO male mice, which was far lower than the 500 ppm in WT mice. These results suggested that decrease and deficiency of ALDH2 activity would significantly increase the sensitivity to ETBE-induced genotoxicity as well as hepatotoxic effects after exposure even to low concentrations of ETBE. Environ. Mol. Mutagen. 60: 145-153, 2019. © 2018 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Zuquan Weng
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
- National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Yuhong Shi
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
| | - Megumi Suda
- National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Yukie Yanagiba
- National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Toshihiro Kawamoto
- Department of Environmental Health, University of Occupational and Environmental Health, Kitakyushu, Japan
| | - Tamie Nakajima
- College of Life and Health Sciences, Chubu University, Nagoya, Japan
| | - Rui-Sheng Wang
- National Institute of Occupational Safety and Health, Kawasaki, Japan
| |
Collapse
|
34
|
Wang RS, Oldham WM, Maron BA, Loscalzo J. Systems Biology Approaches to Redox Metabolism in Stress and Disease States. Antioxid Redox Signal 2018; 29:953-972. [PMID: 29121773 PMCID: PMC6104248 DOI: 10.1089/ars.2017.7256] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 10/12/2017] [Accepted: 11/04/2017] [Indexed: 02/06/2023]
Abstract
SIGNIFICANCE All cellular metabolic processes are tied to the cellular redox environment. Therefore, maintaining redox homeostasis is critically important for normal cell function. Indeed, redox stress contributes to the pathobiology of many human diseases. The cellular redox response system is composed of numerous interconnected components, including free radicals, redox couples, protein thiols, enzymes, metabolites, and transcription factors. Moreover, interactions between and among these factors are regulated in time and space. Owing to their complexity, systems biology approaches to the characterization of the cellular redox response system may provide insights into novel homeostatic mechanisms and methods of therapeutic reprogramming. Recent Advances: The emergence and development of systems biology has brought forth a set of innovative technologies that provide new avenues for studying redox metabolism. This article will review these systems biology approaches and their potential application to the study of redox metabolism in stress and disease states. CRITICAL ISSUES Clarifying the scope of biological intermediaries affected by dysregulated redox metabolism requires methods that are suitable for analyzing big datasets as classical methods that do not account for multiple interactions are unlikely to portray the totality of perturbed metabolic systems. FUTURE DIRECTIONS Given the diverse redox microenvironments within cells, it will be important to improve the spatial resolution of omic approaches. Futures studies on the integration of multiple systems-based methods and heterogeneous omics data for redox metabolism are required to accelerate the development of the field of redox systems biology. Antioxid. Redox Signal. 29, 953-972.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - William M. Oldham
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Bradley A. Maron
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
- Section of Cardiology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts
| | - Joseph Loscalzo
- Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
35
|
Wang H, Chen J, Suda M, Yanagiba Y, Weng Z, Wang RS. Acute inhalation co-exposure to 1,2-dichloropropane and dichloromethane cause liver damage by inhibiting mitochondrial respiration and defense ability in mice. J Appl Toxicol 2018; 39:260-270. [PMID: 30240022 DOI: 10.1002/jat.3715] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 07/19/2018] [Accepted: 07/24/2018] [Indexed: 11/07/2022]
Abstract
1,2-Dichloropropane (1,2-DCP) is used as an industrial solvent, insecticide fumigant and household dry cleaning product. Carcinogenicity caused by long-term exposure to 1,2-DCP is well established. However, the possible liver damage and related toxic mechanisms associated with acute inhalation exposure to 1,2-DCP are rarely reported. In this study, we investigated the effects of individual and combined exposure to 1,2-DCP and dichloromethane (DCM) on mice liver. The results showed that 1,2-DCP significantly caused liver necrosis, possibly due to 1,2-DCP-induced inhibition of the mitochondrial respiratory chain complex I-IV activities, resulting in mitochondrial dysfunction and extreme ATP consumption. Moreover, 1,2-DCP also decreased mitochondrial defense ability by inhibiting the mitochondrial glutathione S-transferase 1 (MGST1) activity, further aggravating liver damage. Additionally, we found that DCM co-exposure potentially enhanced 1,2-DCP toxicity. Our findings suggest that inhibition of mitochondrial function and MGST1 activity play critical roles in modulating 1,2-DCP-induced liver damage. Furthermore, our results contribute to study the new mechanism of mitochondria-dominated signaling pathways underlying liver injury induced by 1,2-DCP and DCM.
Collapse
Affiliation(s)
- Hufei Wang
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
| | - Jiamin Chen
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
| | - Megumi Suda
- Japan National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Yukie Yanagiba
- Japan National Institute of Occupational Safety and Health, Kawasaki, Japan
| | - Zuquan Weng
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China
| | - Rui-Sheng Wang
- Japan National Institute of Occupational Safety and Health, Kawasaki, Japan
| |
Collapse
|
36
|
Toyooka T, Yanagiba Y, Ibuki Y, Wang RS. Cover Image. J Appl Toxicol 2018. [DOI: 10.1002/jat.3706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
37
|
Qi Y, Toyooka T, Kashiwagi H, Yanagiba Y, Koda S, Ohta H, Wang RS. 2,4-Dimethylaniline generates phosphorylated histone H2AX in human urothelial and hepatic cells through reactive oxygen species produced by cytochrome P450 2E1. Arch Toxicol 2018; 92:3093-3101. [DOI: 10.1007/s00204-018-2289-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2018] [Accepted: 08/16/2018] [Indexed: 01/21/2023]
|
38
|
Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA. NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Sci Transl Med 2018; 10:eaap7294. [PMID: 29899023 PMCID: PMC6223025 DOI: 10.1126/scitranslmed.aap7294] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Accepted: 05/23/2018] [Indexed: 12/12/2022]
Abstract
Germline mutations involving small mothers against decapentaplegic-transforming growth factor-β (SMAD-TGF-β) signaling are an important but rare cause of pulmonary arterial hypertension (PAH), which is a disease characterized, in part, by vascular fibrosis and hyperaldosteronism (ALDO). We developed and analyzed a fibrosis protein-protein network (fibrosome) in silico, which predicted that the SMAD3 target neural precursor cell expressed developmentally down-regulated 9 (NEDD9) is a critical ALDO-regulated node underpinning pathogenic vascular fibrosis. Bioinformatics and microscale thermophoresis demonstrated that oxidation of Cys18 in the SMAD3 docking region of NEDD9 impairs SMAD3-NEDD9 protein-protein interactions in vitro. This effect was reproduced by ALDO-induced oxidant stress in cultured human pulmonary artery endothelial cells (HPAECs), resulting in impaired NEDD9 proteolytic degradation, increased NEDD9 complex formation with Nk2 homeobox 5 (NKX2-5), and increased NKX2-5 binding to COL3A1 Up-regulation of NEDD9-dependent collagen III expression corresponded to changes in cell stiffness measured by atomic force microscopy. HPAEC-derived exosomal signaling targeted NEDD9 to increase collagen I/III expression in human pulmonary artery smooth muscle cells, identifying a second endothelial mechanism regulating vascular fibrosis. ALDO-NEDD9 signaling was not affected by treatment with a TGF-β ligand trap and, thus, was not contingent on TGF-β signaling. Colocalization of NEDD9 with collagen III in HPAECs was observed in fibrotic pulmonary arterioles from PAH patients. Furthermore, NEDD9 ablation or inhibition prevented fibrotic vascular remodeling and pulmonary hypertension in animal models of PAH in vivo. These data identify a critical TGF-β-independent posttranslational modification that impairs SMAD3-NEDD9 binding in HPAECs to modulate vascular fibrosis and promote PAH.
Collapse
Affiliation(s)
- Andriy O Samokhin
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Thomas Stephens
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Bradley M Wertheim
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Rui-Sheng Wang
- Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Sara O Vargas
- Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Lai-Ming Yung
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Minwei Cao
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Marcel Brown
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Elena Arons
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Paul B Dieffenbach
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | | | - Majed Matar
- Celsion Corporation, Lawrenceville, NJ 08648, USA
| | - Frederick P Bowman
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Kathleen J Haley
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - George A Alba
- Department of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Stefano M Marino
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Department of Biotechnology, Akdeniz University, Konyaaltı, Antalya 07058, Turkey
| | - Rahul Kumar
- Program in Translational Lung Research, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Ivan O Rosas
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Aaron B Waxman
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - William M Oldham
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Dinesh Khanna
- Division of Rheumatology, University of Michigan Scleroderma Program, Ann Arbor, MI 48109, USA
| | - Brian B Graham
- Program in Translational Lung Research, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Sachiko Seo
- Department of Hematology and Oncology, National Cancer Research Center East, Kashiwa-shi, Chiba-ken 277-8577, Japan
| | - Vadim N Gladyshev
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Paul B Yu
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Laura E Fredenburgh
- Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Joseph Loscalzo
- Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Jane A Leopold
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - Bradley A Maron
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
| |
Collapse
|
39
|
Wang RS, Loscalzo J. Network-Based Disease Module Discovery by a Novel Seed Connector Algorithm with Pathobiological Implications. J Mol Biol 2018; 430:2939-2950. [PMID: 29791871 DOI: 10.1016/j.jmb.2018.05.016] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 04/30/2018] [Accepted: 05/10/2018] [Indexed: 01/09/2023]
Abstract
Understanding the genetic basis of complex diseases is challenging. Prior work shows that disease-related proteins do not typically function in isolation. Rather, they often interact with each other to form a network module that underlies dysfunctional mechanistic pathways. Identifying such disease modules will provide insights into a systems-level understanding of molecular mechanisms of diseases. Owing to the incompleteness of our knowledge of disease proteins and limited information on the biological mediators of pathobiological processes, the key proteins (seed proteins) for many diseases appear scattered over the human protein-protein interactome and form a few small branches, rather than coherent network modules. In this paper, we develop a network-based algorithm, called the Seed Connector algorithm (SCA), to pinpoint disease modules by adding as few additional linking proteins (seed connectors) to the seed protein pool as possible. Such seed connectors are hidden disease module elements that are critical for interpreting the functional context of disease proteins. The SCA aims to connect seed disease proteins so that disease mechanisms and pathways can be decoded based on predicted coherent network modules. We validate the algorithm using a large corpus of 70 complex diseases and binding targets of over 200 drugs, and demonstrate the biological relevance of the seed connectors. Lastly, as a specific proof of concept, we apply the SCA to a set of seed proteins for coronary artery disease derived from a meta-analysis of large-scale genome-wide association studies and obtain a coronary artery disease module enriched with important disease-related signaling pathways and drug targets not previously recognized.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Joseph Loscalzo
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
| |
Collapse
|
40
|
Toyooka T, Yanagiba Y, Ibuki Y, Wang RS. Trichloroethylene exposure results in the phosphorylation of histone H2AX in a human hepatic cell line through cytochrome P450 2E1-mediated oxidative stress. J Appl Toxicol 2018; 38:1224-1232. [PMID: 29722447 DOI: 10.1002/jat.3632] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Revised: 03/16/2018] [Accepted: 03/22/2018] [Indexed: 01/21/2023]
Abstract
Trichloroethylene (TCE), a chlorinated hydrocarbon, was recently reclassified as a human carcinogen by the International Agency for Research on Cancer. Genotoxic events are known to be crucial steps in the initiation of cancer. The genotoxic properties of TCE have been examined in many studies using a standard battery of genotoxicity tests both in vitro and in vivo. However, consistent results have not been obtained, and studies investigating the mechanism behind the genotoxicity of this compound are lacking. In the present study, we examined the genotoxicity of TCE by assessing phosphorylated histone H2AX (γ-H2AX), a new sensitive and reliable marker of DNA damage, in WRL-68 cells, cultured human hepatocytes and mouse livers. Our results showed that TCE exposure results in the generation of γ-H2AX, both in vitro and in vivo. By investigating the in vitro mechanism, we found that TCE increases the levels of intracellular reactive oxygen species (ROS) and that this increase in ROS levels is attenuated in the presence of disulfiram, a specific cytochrome P450 2E1 (CYP2E1) inhibitor. Furthermore, γ-H2AX induced by TCE was also attenuated by CYP2E1 inhibitors and the antioxidant N-acetylcysteine. These results suggested that ROS, produced via cytochrome P450 2E1-mediated metabolic processing, is a major causal factor for γ-H2AX generation upon exposure to TCE.
Collapse
Affiliation(s)
- Tatsushi Toyooka
- Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Japan
| | - Yukie Yanagiba
- Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Japan
| | - Yuko Ibuki
- Graduate Division of Nutritional and Environmental Sciences, University of Shizuoka, Japan
| | - Rui-Sheng Wang
- Industrial Toxicology and Health Effects Research Group, National Institute of Occupational Safety and Health, Japan
| |
Collapse
|
41
|
Oldham WM, Oliveira RKF, Wang RS, Opotowsky AR, Rubins DM, Hainer J, Wertheim BM, Alba GA, Choudhary G, Tornyos A, MacRae CA, Loscalzo J, Leopold JA, Waxman AB, Olschewski H, Kovacs G, Systrom DM, Maron BA. Network Analysis to Risk Stratify Patients With Exercise Intolerance. Circ Res 2018; 122:864-876. [PMID: 29437835 PMCID: PMC5924425 DOI: 10.1161/circresaha.117.312482] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Revised: 01/30/2018] [Accepted: 02/01/2018] [Indexed: 01/09/2023]
Abstract
RATIONALE Current methods assessing clinical risk because of exercise intolerance in patients with cardiopulmonary disease rely on a small subset of traditional variables. Alternative strategies incorporating the spectrum of factors underlying prognosis in at-risk patients may be useful clinically, but are lacking. OBJECTIVE Use unbiased analyses to identify variables that correspond to clinical risk in patients with exercise intolerance. METHODS AND RESULTS Data from 738 consecutive patients referred for invasive cardiopulmonary exercise testing at a single center (2011-2015) were analyzed retrospectively (derivation cohort). A correlation network of invasive cardiopulmonary exercise testing parameters was assembled using |r|>0.5. From an exercise network of 39 variables (ie, nodes) and 98 correlations (ie, edges) corresponding to P<9.5e-46 for each correlation, we focused on a subnetwork containing peak volume of oxygen consumption (pVo2) and 9 linked nodes. K-mean clustering based on these 10 variables identified 4 novel patient clusters characterized by significant differences in 44 of 45 exercise measurements (P<0.01). Compared with a probabilistic model, including 23 independent predictors of pVo2 and pVo2 itself, the network model was less redundant and identified clusters that were more distinct. Cluster assignment from the network model was predictive of subsequent clinical events. For example, a 4.3-fold (P<0.0001; 95% CI, 2.2-8.1) and 2.8-fold (P=0.0018; 95% CI, 1.5-5.2) increase in hazard for age- and pVo2-adjusted all-cause 3-year hospitalization, respectively, were observed between the highest versus lowest risk clusters. Using these data, we developed the first risk-stratification calculator for patients with exercise intolerance. When applying the risk calculator to patients in 2 independent invasive cardiopulmonary exercise testing cohorts (Boston and Graz, Austria), we observed a clinical risk profile that paralleled the derivation cohort. CONCLUSIONS Network analyses were used to identify novel exercise groups and develop a point-of-care risk calculator. These data expand the range of useful clinical variables beyond pVo2 that predict hospitalization in patients with exercise intolerance.
Collapse
Affiliation(s)
- William M Oldham
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Rudolf K F Oliveira
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Rui-Sheng Wang
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Alexander R Opotowsky
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - David M Rubins
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Jon Hainer
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Bradley M Wertheim
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - George A Alba
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Gaurav Choudhary
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Adrienn Tornyos
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Calum A MacRae
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Joseph Loscalzo
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Jane A Leopold
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Aaron B Waxman
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Horst Olschewski
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Gabor Kovacs
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - David M Systrom
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.)
| | - Bradley A Maron
- From the Department of Medicine (W.M.O., R.K.F.O., R.-S.W., D.M.R., B.M.W., C.A.M., J.L., A.B.W., D.M.S., J.A.L.), Division of Pulmonary and Critical Care Medicine (W.M.O., B.M.W., A.B.W., D.M.S.), Division of Cardiovascular Medicine (A.R.O., C.A.M., J.L., J.A.L., B.A.M.), and Department of Radiology (J.H.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), Brazil (R.K.F.O.); Department of Cardiology, Boston Children's Hospital and Harvard Medical School, MA (A.R.O.); Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (G.A.A.); Division of Cardiology, Department of Medicine, Providence Veterans Affairs Medical Center and Alpert Medical School of Brown University, Providence, RI (G.C.); Department of Pulmonology, Medical University of Graz, Austria (A.T., H.O., G.K.); Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria (A.T., H.O., G.K.); and Department of Cardiology, Boston VA Healthcare System, MA (B.A.M.).
| |
Collapse
|
42
|
Abstract
SIGNIFICANCE The nicotinamide adenine dinucleotide (NAD+)/reduced NAD+ (NADH) and NADP+/reduced NADP+ (NADPH) redox couples are essential for maintaining cellular redox homeostasis and for modulating numerous biological events, including cellular metabolism. Deficiency or imbalance of these two redox couples has been associated with many pathological disorders. Recent Advances: Newly identified biosynthetic enzymes and newly developed genetically encoded biosensors enable us to understand better how cells maintain compartmentalized NAD(H) and NADP(H) pools. The concept of redox stress (oxidative and reductive stress) reflected by changes in NAD(H)/NADP(H) has increasingly gained attention. The emerging roles of NAD+-consuming proteins in regulating cellular redox and metabolic homeostasis are active research topics. CRITICAL ISSUES The biosynthesis and distribution of cellular NAD(H) and NADP(H) are highly compartmentalized. It is critical to understand how cells maintain the steady levels of these redox couple pools to ensure their normal functions and simultaneously avoid inducing redox stress. In addition, it is essential to understand how NAD(H)- and NADP(H)-utilizing enzymes interact with other signaling pathways, such as those regulated by hypoxia-inducible factor, to maintain cellular redox homeostasis and energy metabolism. FUTURE DIRECTIONS Additional studies are needed to investigate the inter-relationships among compartmentalized NAD(H)/NADP(H) pools and how these two dinucleotide redox couples collaboratively regulate cellular redox states and cellular metabolism under normal and pathological conditions. Furthermore, recent studies suggest the utility of using pharmacological interventions or nutrient-based bioactive NAD+ precursors as therapeutic interventions for metabolic diseases. Thus, a better understanding of the cellular functions of NAD(H) and NADP(H) may facilitate efforts to address a host of pathological disorders effectively. Antioxid. Redox Signal. 28, 251-272.
Collapse
Affiliation(s)
- Wusheng Xiao
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts
| | - Rui-Sheng Wang
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts
| | - Diane E Handy
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts
| | - Joseph Loscalzo
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts
| |
Collapse
|
43
|
Abstract
The Minimum Error Correction (MEC) is an important model for haplotype reconstruction from SNP fragments. However, this model is effective only when the error rate of SNP fragments is low. In this paper, we propose a new computational model called Minimum Conflict Individual Haplotyping (MCIH) as an extension to MEC. In contrast to the conventional approaches, the new model employs SNP fragment information and also related genotype information, thereby a high accurate inference can be expected. We first prove the MCIH problem to be NP-hard. To evaluate the practicality of the new model we design an exact algorithm (a dynamic programming procedure) to implement MCIH on a special data structure. The numerical experience indicates that it is fairly effective to use MCIH at the cost of related genotype information, especially in the case of SNP fragments with a high error rate. Moreover, we present a feed-forward neural network algorithm to solve MCIH for general data structure and large size instances. Numerical results on real biological data and simulation data show that the algorithm works well and MCIH is a potential alternative in individual haplotyping.
Collapse
Affiliation(s)
- Xiang-Sun Zhang
- Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing 100080, China
| | - Rui-Sheng Wang
- School of Information, Renmin University of China, Beijing 100872
| | - Ling-Yun Wu
- Academy of Mathematics and Systems Science, Chinese Academy of Sciences, Beijing 100080, China
| | - Wei Zhang
- North Carolina State University, Raleigh, NC 27695-7906, U.S.A
| |
Collapse
|
44
|
Wang RS, Loscalzo J. Illuminating drug action by network integration of disease genes: a case study of myocardial infarction. Mol Biosyst 2017; 12:1653-66. [PMID: 27004607 DOI: 10.1039/c6mb00052e] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Drug discovery has produced many successful therapeutic agents; however, most of these drugs were developed without a deep understanding of the system-wide mechanisms of action responsible for their indications. Gene-disease associations produced by molecular and genetic studies of complex diseases provide great opportunities for a system-level understanding of drug activity. In this study, we focused on acute myocardial infarction (MI) and conducted an integrative network analysis to illuminate drug actions. We integrated MI drugs, MI drug interactors, drug targets, and MI disease genes into the human interactome and showed that MI drug targets are significantly proximate to MI disease proteins. We then constructed a bipartite network of MI-related drug targets and MI disease proteins and derived 12 drug-target-disease (DTD) modules. We assessed the biological relevance of these modules and demonstrated the benefits of incorporating disease genes. The results indicate that DTD modules provide insights into the mechanisms of action of MI drugs and the cardiovascular (side) effects of non-MI drugs.
Collapse
Affiliation(s)
- Rui-Sheng Wang
- Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA.
| | - Joseph Loscalzo
- Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA.
| |
Collapse
|
45
|
Wang RS, Hall KT, Giulianini F, Passow D, Kaptchuk TJ, Loscalzo J. Network analysis of the genomic basis of the placebo effect. JCI Insight 2017; 2:93911. [PMID: 28570268 DOI: 10.1172/jci.insight.93911] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Accepted: 05/02/2017] [Indexed: 12/13/2022] Open
Abstract
The placebo effect is a phenomenon in which patients who are given an inactive treatment (e.g., inert pill) show a perceived or actual improvement in a medical condition. Placebo effects in clinical trials have been investigated for many years especially because placebo treatments often serve as the control arm of randomized clinical trial designs. Recent observations suggest that placebo effects may be modified by genetics. This observation has given rise to the term "placebome," which refers to a group of genome-related mediators that affect an individual's response to placebo treatments. In this study, we conduct a network analysis of the placebome and identify a placebome module in the comprehensive human interactome using a seed-connector algorithm. The placebome module is significantly enriched with neurotransmitter signaling pathways and brain-specific proteins. We validate the placebome module using a large cohort of the Women's Genome Health Study (WGHS) trial and demonstrate that the placebome module is significantly enriched with genes whose SNPs modify the outcome in the placebo arm of the trial. To gain insights into placebo effects in different diseases and drug treatments, we use a network proximity measure to examine the closeness of the placebome module to different disease modules and drug target modules. The results demonstrate that the network proximity of the placebome module to disease modules in the interactome significantly correlates with the strength of the placebo effect in the corresponding diseases. The proximity of the placebome module to molecular pathways affected by certain drug classes indicates the existence of placebo-drug interactions. This study is helpful for understanding the molecular mechanisms mediating the placebo response, and sets the stage for minimizing its effects in clinical trials and for developing therapeutic strategies that intentionally engage it.
Collapse
Affiliation(s)
| | - Kathryn T Hall
- Department of Medicine and.,Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Franco Giulianini
- Department of Medicine and.,Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Dani Passow
- Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Ted J Kaptchuk
- Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | | |
Collapse
|
46
|
|
47
|
Yanagiba Y, Suda M, Toyooka T, Wang RS. [Chemical management and occupational cholangiocarcinoma among workers in printing industry]. Sangyo Eiseigaku Zasshi 2016; 58:78-83. [PMID: 26983494 DOI: 10.1539/sangyoeisei.wadai15005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
48
|
Song C, Yang L, Wang RS. Uniform integrability of fuzzy variable sequences. IFS 2016. [DOI: 10.3233/ifs-151868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Chunxia Song
- College of People’s Armed Force, Hebei University, Shijiazhuang, China
| | - Lanzhen Yang
- College of Mathematics and Information Science, Hebei University, Baoding, China
| | - Rui-Sheng Wang
- School of Information, Renmin University of China, Beijing, China
| |
Collapse
|
49
|
Wang K, Wan M, Wang RS, Weng Z. Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events. J Med Internet Res 2016; 18:e76. [PMID: 27036325 PMCID: PMC4833875 DOI: 10.2196/jmir.4541] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Revised: 12/02/2015] [Accepted: 01/04/2016] [Indexed: 12/21/2022] Open
Abstract
Background Drug repositioning refers to the process of developing new indications for existing drugs. As a phenotypic indicator of drug response in humans, clinical side effects may provide straightforward signals and unique opportunities for drug repositioning. Objective We aimed to identify drugs frequently associated with hypotension adverse reactions (ie, the opposite condition of hypertension), which could be potential candidates as antihypertensive agents. Methods We systematically searched the electronic records of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) through the openFDA platform to assess the association between hypotension incidence and antihypertensive therapeutic effect regarding a list of 683 drugs. Results Statistical analysis of FAERS data demonstrated that those drugs frequently co-occurring with hypotension events were more likely to have antihypertensive activity. Ranked by the statistical significance of frequent hypotension reporting, the well-known antihypertensive drugs were effectively distinguished from others (with an area under the receiver operating characteristic curve > 0.80 and a normalized discounted cumulative gain of 0.77). In addition, we found a series of antihypertensive agents (particularly drugs originally developed for treating nervous system diseases) among the drugs with top significant reporting, suggesting the good potential of Web-based and data-driven drug repositioning. Conclusions We found several candidate agents among the hypotension-related drugs on our list that may be redirected for lowering blood pressure. More important, we showed that a pharmacovigilance system could alternatively be used to identify antihypertensive agents and sustainably create opportunities for drug repositioning.
Collapse
Affiliation(s)
- Kejian Wang
- CoMed Technology & Consulting Co., Ltd., Hong Kong, China
| | | | | | | |
Collapse
|
50
|
Aguilar M, Aisa D, Alpat B, Alvino A, Ambrosi G, Andeen K, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Battarbee M, Battiston R, Bazo J, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, Bizzaglia S, Bizzarri M, Boella G, de Boer W, Bollweg K, Bonnivard V, Borgia B, Borsini S, Boschini MJ, Bourquin M, Burger J, Cadoux F, Cai XD, Capell M, Caroff S, Casaus J, Castellini G, Cernuda I, Cerreta D, Cervelli F, Chae MJ, Chang YH, Chen AI, Chen GM, Chen H, Chen HS, Cheng L, Chou HY, Choumilov E, Choutko V, Chung CH, Clark C, Clavero R, Coignet G, Consolandi C, Contin A, Corti C, Gil EC, Coste B, Creus W, Crispoltoni M, Cui Z, Dai YM, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Masso L, Dimiccoli F, Díaz C, von Doetinchem P, Donnini F, Duranti M, D'Urso D, Egorov A, Eline A, Eppling FJ, Eronen T, Fan YY, Farnesini L, Feng J, Fiandrini E, Fiasson A, Finch E, Fisher P, Formato V, Galaktionov Y, Gallucci G, García B, García-López R, Gargiulo C, Gast H, Gebauer I, Gervasi M, Ghelfi A, Giovacchini F, Goglov P, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guandalini C, Guerri I, Guo KH, Haas D, Habiby M, Haino S, Han KC, He ZH, Heil M, Hoffman J, Hsieh TH, Huang ZC, Huh C, Incagli M, Ionica M, Jang WY, Jinchi H, Kanishev K, Kim GN, Kim KS, Kirn T, Korkmaz MA, Kossakowski R, Kounina O, Kounine A, Koutsenko V, Krafczyk MS, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Li HL, Li JQ, Li JQ, Li Q, Li Q, Li TX, Li W, Li Y, Li ZH, Li ZY, Lim S, Lin CH, Lipari P, Lippert T, Liu D, Liu H, Liu H, Lolli M, Lomtadze T, Lu MJ, Lu SQ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Lv SS, Majka R, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Morescalchi L, Mott P, Müller M, Nelson T, Ni JQ, Nikonov N, Nozzoli F, Nunes P, Obermeier A, Oliva A, Orcinha M, Palmonari F, Palomares C, Paniccia M, Papi A, Pauluzzi M, Pedreschi E, Pensotti S, Pereira R, Picot-Clemente N, Pilo F, Piluso A, Pizzolotto C, Plyaskin V, Pohl M, Poireau V, Putze A, Quadrani L, Qi XM, Qin X, Qu ZY, Räihä T, Rancoita PG, Rapin D, Ricol JS, Rodríguez I, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Sandweiss J, Saouter P, Schael S, Schmidt SM, von Dratzig AS, Schwering G, Scolieri G, Seo ES, Shan BS, Shan YH, Shi JY, Shi XY, Shi YM, Siedenburg T, Son D, Song JW, Spada F, Spinella F, Sun W, Sun WH, Tacconi M, Tang CP, Tang XW, Tang ZC, Tao L, Tescaro D, Ting SCC, Ting SM, Tomassetti N, Torsti J, Türkoğlu C, Urban T, Vagelli V, Valente E, Vannini C, Valtonen E, Vaurynovich S, Vecchi M, Velasco M, Vialle JP, Vitale V, Vitillo S, Wang LQ, Wang NH, Wang QL, Wang RS, Wang X, Wang ZX, Weng ZL, Whitman K, Wienkenhöver J, Willenbrock M, Wu H, Wu X, Xia X, Xie M, Xie S, Xiong RQ, Xu NS, Xu W, Yan Q, Yang J, Yang M, Yang Y, Ye QH, Yi H, Yu YJ, Yu ZQ, Zeissler S, Zhang C, Zhang JH, Zhang MT, Zhang SD, Zhang SW, Zhang XB, Zhang Z, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Precision Measurement of the Helium Flux in Primary Cosmic Rays of Rigidities 1.9 GV to 3 TV with the Alpha Magnetic Spectrometer on the International Space Station. Phys Rev Lett 2015; 115:211101. [PMID: 26636836 DOI: 10.1103/physrevlett.115.211101] [Citation(s) in RCA: 81] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Indexed: 06/05/2023]
Abstract
Knowledge of the precise rigidity dependence of the helium flux is important in understanding the origin, acceleration, and propagation of cosmic rays. A precise measurement of the helium flux in primary cosmic rays with rigidity (momentum/charge) from 1.9 GV to 3 TV based on 50 million events is presented and compared to the proton flux. The detailed variation with rigidity of the helium flux spectral index is presented for the first time. The spectral index progressively hardens at rigidities larger than 100 GV. The rigidity dependence of the helium flux spectral index is similar to that of the proton spectral index though the magnitudes are different. Remarkably, the spectral index of the proton to helium flux ratio increases with rigidity up to 45 GV and then becomes constant; the flux ratio above 45 GV is well described by a single power law.
Collapse
Affiliation(s)
- M Aguilar
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - D Aisa
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - B Alpat
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - A Alvino
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - G Ambrosi
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - K Andeen
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology (KIT), D-76128 Karlsruhe, Germany
| | - L Arruda
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), P-1000 Lisboa, Portugal
| | - N Attig
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, D-52425 Jülich, Germany
| | - P Azzarello
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - A Bachlechner
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - F Barao
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), P-1000 Lisboa, Portugal
| | - A Barrau
- Laboratoire de Physique Subatomique et de Cosmologie (LPSC), CNRS/IN2P3 and Université Grenoble-Alpes, F-38026 Grenoble, France
| | - L Barrin
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | | | - L Basara
- INFN TIFPA, I-38123 Povo, Trento, Italy
| | - M Battarbee
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland
| | - R Battiston
- INFN TIFPA, I-38123 Povo, Trento, Italy
- Università di Trento, I-38123 Povo, Trento, Italy
| | - J Bazo
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - U Becker
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Behlmann
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - B Beischer
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - J Berdugo
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - B Bertucci
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - V Bindi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - S Bizzaglia
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - M Bizzarri
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - G Boella
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
- Università di Milano-Bicocca, I-20126 Milano, Italy
| | - W de Boer
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology (KIT), D-76128 Karlsruhe, Germany
| | - K Bollweg
- National Aeronautics and Space Administration Johnson Space Center (JSC), and Jacobs-Sverdrup, Houston, Texas 77058, USA
| | - V Bonnivard
- Laboratoire de Physique Subatomique et de Cosmologie (LPSC), CNRS/IN2P3 and Université Grenoble-Alpes, F-38026 Grenoble, France
| | - B Borgia
- INFN Sezione di Roma 1, I-00185 Roma, Italy
- Università di Roma La Sapienza, I-00185 Roma, Italy
| | - S Borsini
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - M J Boschini
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - M Bourquin
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - J Burger
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F Cadoux
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - X D Cai
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Capell
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - S Caroff
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - J Casaus
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | | | - I Cernuda
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - D Cerreta
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - F Cervelli
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - M J Chae
- Department of Physics, Ewha Womans University, Seoul 120-750, Korea
| | - Y H Chang
- National Central University (NCU), Chung-Li, Tao Yuan 32054, Taiwan
| | - A I Chen
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G M Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - H Chen
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H S Chen
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - L Cheng
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - H Y Chou
- National Central University (NCU), Chung-Li, Tao Yuan 32054, Taiwan
| | - E Choumilov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Choutko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - C H Chung
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - C Clark
- National Aeronautics and Space Administration Johnson Space Center (JSC), and Jacobs-Sverdrup, Houston, Texas 77058, USA
| | - R Clavero
- Instituto de Astrofísica de Canarias (IAC), E-38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - G Coignet
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - C Consolandi
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - A Contin
- INFN Sezione di Bologna, I-40126 Bologna, Italy
- Università di Bologna, I-40126 Bologna, Italy
| | - C Corti
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - E Cortina Gil
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - B Coste
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
- INFN TIFPA, I-38123 Povo, Trento, Italy
| | - W Creus
- National Central University (NCU), Chung-Li, Tao Yuan 32054, Taiwan
| | - M Crispoltoni
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - Z Cui
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Y M Dai
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - C Delgado
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - S Della Torre
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - M B Demirköz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - L Derome
- Laboratoire de Physique Subatomique et de Cosmologie (LPSC), CNRS/IN2P3 and Université Grenoble-Alpes, F-38026 Grenoble, France
| | - S Di Falco
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - L Di Masso
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - F Dimiccoli
- INFN TIFPA, I-38123 Povo, Trento, Italy
- Università di Trento, I-38123 Povo, Trento, Italy
| | - C Díaz
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - P von Doetinchem
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - F Donnini
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - M Duranti
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - D D'Urso
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - A Egorov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Eline
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - F J Eppling
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - T Eronen
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland
| | - Y Y Fan
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - L Farnesini
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - J Feng
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - E Fiandrini
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - A Fiasson
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - E Finch
- Physics Department, Yale University, New Haven, Connecticut 06520, USA
| | - P Fisher
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Formato
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - Y Galaktionov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G Gallucci
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - B García
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - R García-López
- Instituto de Astrofísica de Canarias (IAC), E-38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - C Gargiulo
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
| | - H Gast
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - I Gebauer
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology (KIT), D-76128 Karlsruhe, Germany
| | - M Gervasi
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
- Università di Milano-Bicocca, I-20126 Milano, Italy
| | - A Ghelfi
- Laboratoire de Physique Subatomique et de Cosmologie (LPSC), CNRS/IN2P3 and Université Grenoble-Alpes, F-38026 Grenoble, France
| | - F Giovacchini
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - P Goglov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Gong
- Southeast University (SEU), Nanjing 210096, China
| | - C Goy
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - V Grabski
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), México, D. F. 01000 Mexico
| | - D Grandi
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - M Graziani
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | | | - I Guerri
- INFN Sezione di Pisa, I-56100 Pisa, Italy
- Università di Pisa, I-56100 Pisa, Italy
| | - K H Guo
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - D Haas
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - M Habiby
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - S Haino
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - K C Han
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 325, Taiwan
| | - Z H He
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - M Heil
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Hoffman
- National Central University (NCU), Chung-Li, Tao Yuan 32054, Taiwan
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - T H Hsieh
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z C Huang
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - C Huh
- CHEP, Kyungpook National University, 702-701 Daegu, Korea
| | - M Incagli
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - M Ionica
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - W Y Jang
- CHEP, Kyungpook National University, 702-701 Daegu, Korea
| | - H Jinchi
- National Chung-Shan Institute of Science and Technology (NCSIST), Longtan, Tao Yuan 325, Taiwan
| | - K Kanishev
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
- INFN TIFPA, I-38123 Povo, Trento, Italy
- Università di Trento, I-38123 Povo, Trento, Italy
| | - G N Kim
- CHEP, Kyungpook National University, 702-701 Daegu, Korea
| | - K S Kim
- CHEP, Kyungpook National University, 702-701 Daegu, Korea
| | - Th Kirn
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - M A Korkmaz
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - R Kossakowski
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - O Kounina
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - A Kounine
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - V Koutsenko
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M S Krafczyk
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - G La Vacca
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - E Laudi
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | - G Laurenti
- INFN Sezione di Bologna, I-40126 Bologna, Italy
| | - I Lazzizzera
- INFN TIFPA, I-38123 Povo, Trento, Italy
- Università di Trento, I-38123 Povo, Trento, Italy
| | - A Lebedev
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H T Lee
- Academia Sinica Grid Center (ASGC), Nankang, Taipei 11529, Taiwan
| | - S C Lee
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - C Leluc
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - H L Li
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - J Q Li
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - Q Li
- Southeast University (SEU), Nanjing 210096, China
| | - Q Li
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - T X Li
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - W Li
- Beihang University (BUAA), Beijing 100191, China
| | - Y Li
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - Z H Li
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - Z Y Li
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - S Lim
- CHEP, Kyungpook National University, 702-701 Daegu, Korea
| | - C H Lin
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - P Lipari
- INFN Sezione di Roma 1, I-00185 Roma, Italy
| | - T Lippert
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, D-52425 Jülich, Germany
| | - D Liu
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - H Liu
- Southeast University (SEU), Nanjing 210096, China
| | - Hu Liu
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - M Lolli
- INFN Sezione di Bologna, I-40126 Bologna, Italy
| | - T Lomtadze
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - M J Lu
- INFN TIFPA, I-38123 Povo, Trento, Italy
| | - S Q Lu
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - Y S Lu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - K Luebelsmeyer
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - F Luo
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - J Z Luo
- Southeast University (SEU), Nanjing 210096, China
| | - S S Lv
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - R Majka
- Physics Department, Yale University, New Haven, Connecticut 06520, USA
| | - C Mañá
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - J Marín
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - T Martin
- National Aeronautics and Space Administration Johnson Space Center (JSC), and Jacobs-Sverdrup, Houston, Texas 77058, USA
| | - G Martínez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - N Masi
- INFN Sezione di Bologna, I-40126 Bologna, Italy
| | - D Maurin
- Laboratoire de Physique Subatomique et de Cosmologie (LPSC), CNRS/IN2P3 and Université Grenoble-Alpes, F-38026 Grenoble, France
| | - A Menchaca-Rocha
- Instituto de Física, Universidad Nacional Autónoma de México (UNAM), México, D. F. 01000 Mexico
| | - Q Meng
- Southeast University (SEU), Nanjing 210096, China
| | - D C Mo
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | | | - P Mott
- National Aeronautics and Space Administration Johnson Space Center (JSC), and Jacobs-Sverdrup, Houston, Texas 77058, USA
| | - M Müller
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - T Nelson
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - J Q Ni
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - N Nikonov
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology (KIT), D-76128 Karlsruhe, Germany
| | - F Nozzoli
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - P Nunes
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), P-1000 Lisboa, Portugal
| | - A Obermeier
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Oliva
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - M Orcinha
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), P-1000 Lisboa, Portugal
| | - F Palmonari
- INFN Sezione di Bologna, I-40126 Bologna, Italy
- Università di Bologna, I-40126 Bologna, Italy
| | - C Palomares
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - M Paniccia
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - A Papi
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - M Pauluzzi
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | | | - S Pensotti
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
- Università di Milano-Bicocca, I-20126 Milano, Italy
| | - R Pereira
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | | | - F Pilo
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - A Piluso
- INFN Sezione di Perugia, I-06100 Perugia, Italy
- Università di Perugia, I-06100 Perugia, Italy
| | | | - V Plyaskin
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Pohl
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - V Poireau
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - A Putze
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - L Quadrani
- INFN Sezione di Bologna, I-40126 Bologna, Italy
- Università di Bologna, I-40126 Bologna, Italy
| | - X M Qi
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - X Qin
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - Z Y Qu
- Institute of Physics, Academia Sinica, Nankang, Taipei 11529, Taiwan
| | - T Räihä
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - P G Rancoita
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - D Rapin
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - J S Ricol
- Laboratoire de Physique Subatomique et de Cosmologie (LPSC), CNRS/IN2P3 and Université Grenoble-Alpes, F-38026 Grenoble, France
| | - I Rodríguez
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - S Rosier-Lees
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - A Rozhkov
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - D Rozza
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - R Sagdeev
- East-West Center for Space Science, University of Maryland, College Park, Maryland 20742, USA
| | - J Sandweiss
- Physics Department, Yale University, New Haven, Connecticut 06520, USA
| | - P Saouter
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - S Schael
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - S M Schmidt
- Jülich Supercomputing Centre and JARA-FAME, Research Centre Jülich, D-52425 Jülich, Germany
| | - A Schulz von Dratzig
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - G Schwering
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - G Scolieri
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - E S Seo
- IPST, University of Maryland, College Park, Maryland 20742, USA
| | - B S Shan
- Beihang University (BUAA), Beijing 100191, China
| | - Y H Shan
- Beihang University (BUAA), Beijing 100191, China
| | - J Y Shi
- Southeast University (SEU), Nanjing 210096, China
| | - X Y Shi
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Y M Shi
- Shanghai Jiaotong University (SJTU), Shanghai 200030, China
| | - T Siedenburg
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - D Son
- CHEP, Kyungpook National University, 702-701 Daegu, Korea
| | - J W Song
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - F Spada
- INFN Sezione di Roma 1, I-00185 Roma, Italy
| | - F Spinella
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - W Sun
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - W H Sun
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Tacconi
- European Organization for Nuclear Research (CERN), CH-1211 Geneva 23, Switzerland
- INFN Sezione di Milano-Bicocca, I-20126 Milano, Italy
| | - C P Tang
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - X W Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - Z C Tang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - L Tao
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - D Tescaro
- Instituto de Astrofísica de Canarias (IAC), E-38205 La Laguna, and Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - Samuel C C Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - S M Ting
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - N Tomassetti
- Laboratoire de Physique Subatomique et de Cosmologie (LPSC), CNRS/IN2P3 and Université Grenoble-Alpes, F-38026 Grenoble, France
| | - J Torsti
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland
| | - C Türkoğlu
- Department of Physics, Middle East Technical University (METU), 06800 Ankara, Turkey
| | - T Urban
- National Aeronautics and Space Administration Johnson Space Center (JSC), and Jacobs-Sverdrup, Houston, Texas 77058, USA
| | - V Vagelli
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology (KIT), D-76128 Karlsruhe, Germany
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - E Valente
- INFN Sezione di Roma 1, I-00185 Roma, Italy
- Università di Roma La Sapienza, I-00185 Roma, Italy
| | - C Vannini
- INFN Sezione di Pisa, I-56100 Pisa, Italy
| | - E Valtonen
- Space Research Laboratory, Department of Physics and Astronomy, University of Turku, FI-20014 Turku, Finland
| | - S Vaurynovich
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - M Vecchi
- Instituto de Fìsica de São Carlos, Universidade de São Paulo, CP 369, 13560-970 São Carlos, São Paulo, Brazil
| | - M Velasco
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - J P Vialle
- Laboratoire d'Annecy-le-Vieux de Physique des Particules (LAPP), CNRS/IN2P3 and Université de Savoie Mont Blanc, F-74941 Annecy-le-Vieux, France
| | - V Vitale
- INFN Sezione di Perugia, I-06100 Perugia, Italy
| | - S Vitillo
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - L Q Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - N H Wang
- Shandong University (SDU), Jinan, Shandong 250100, China
| | - Q L Wang
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - R S Wang
- Shanghai Jiaotong University (SJTU), Shanghai 200030, China
| | - X Wang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Z X Wang
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - Z L Weng
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - K Whitman
- Physics and Astronomy Department, University of Hawaii, Honolulu, Hawaii 96822, USA
| | - J Wienkenhöver
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - M Willenbrock
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - H Wu
- Southeast University (SEU), Nanjing 210096, China
| | - X Wu
- DPNC, Université de Genève, CH-1211 Genève 4, Switzerland
| | - X Xia
- Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), E-28040 Madrid, Spain
| | - M Xie
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - S Xie
- Shanghai Jiaotong University (SJTU), Shanghai 200030, China
| | - R Q Xiong
- Southeast University (SEU), Nanjing 210096, China
| | - N S Xu
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - W Xu
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - Q Yan
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - J Yang
- Department of Physics, Ewha Womans University, Seoul 120-750, Korea
| | - M Yang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - Y Yang
- National Cheng Kung University, Tainan 701, Taiwan
| | - Q H Ye
- Shanghai Jiaotong University (SJTU), Shanghai 200030, China
| | - H Yi
- Southeast University (SEU), Nanjing 210096, China
| | - Y J Yu
- Institute of Electrical Engineering (IEE), Chinese Academy of Sciences, Beijing 100190, China
| | - Z Q Yu
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - S Zeissler
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology (KIT), D-76128 Karlsruhe, Germany
| | - C Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - J H Zhang
- Southeast University (SEU), Nanjing 210096, China
| | - M T Zhang
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - S D Zhang
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| | - S W Zhang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - X B Zhang
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - Z Zhang
- Sun Yat-Sen University (SYSU), Guangzhou 510275, China
| | - Z M Zheng
- Beihang University (BUAA), Beijing 100191, China
| | - H L Zhuang
- Institute of High Energy Physics (IHEP), Chinese Academy of Sciences, Beijing 100039, China
| | - V Zhukov
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - A Zichichi
- INFN Sezione di Bologna, I-40126 Bologna, Italy
- Università di Bologna, I-40126 Bologna, Italy
| | - N Zimmermann
- I. Physics Institute and JARA-FAME, RWTH Aachen University, D-52056 Aachen, Germany
| | - P Zuccon
- Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts 02139, USA
| |
Collapse
|